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Abstract 
Background 
The majority of invasive fungal disease in South African hospitals is HIV-related or associated 
with another secondary immunodeficiency e.g. haematopoietic stem cell transplant. After 
excluding secondary immunodeficiency, a detailed immune work-up can lead to a diagnosis of  
primary immunodeficiency. 
Objective 
To detail an appropriate step-wise immunological work-up for a series of patients with invasive 
fungal diseases and possible underlying primary immune deficiency. 
Methods 
Detailed review of all culture- or histologically confirmed cases of invasive fungal disease 
(IFD) at Groote Schuur Hospital between 2007-2017. Step-wise immunological work-up of  
IFD patients with no secondary immunodeficiency. Clinical characteristics and step-wise 
immunological profiles were evaluated. 
Results 
Sixty-seven adults with IFD were identified; 72% (48/67) were HIV-related. 8/19 HIV-
negative cases were either deceased (4) or lost-to-follow-up (4). Work-up of the remaining 11 
cases found five with non-HIV secondary immunodeficiencies (Lupus, liver transplant, end-
stage renal failure and haematological malignancy). A primary immunodeficiency was 
suspected in six cases, but 1 case of cutaneous sporotrichosis was excluded; with five cases (4 
with disseminated Cryptococcus neoformans and 1 with cerebral aspergillosis) undergoing 
detailed immune work-up. A case of idiopathic CD4 lymphopenia was diagnosed; but all other 
cases had no evidence of neutrophil or a cell-mediated immune defect; including investigations 
of naïve and memory T-cell subsets and cytokine responses to PHA and candida. All cases 
were noted to have low baseline vaccine responses and Vitamin D deficiency. 
Conclusion 
Invasive fungal disease is predominantly associated with HIV and secondary 
immunodeficiency in South Africa. Known primary immunodeficiencies can be identified with 
basic immune work-up; but no obvious functional immune defect is evident in the majority of 
these cases.  
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Background 
Introduction 
Whereas fungi are ubiquitous, only a minority cause infection in humans. Innate and adaptive 
immune responses are usually effective in preventing disease or restricting to non-invasive 
infections. Invasive fungal infections occur whenever there’s failure of these immune 
mechanisms to contain invading fungal elements; often leading to severe and disseminated 
disease. Secondary immunodeficiencies, especially HIV/AIDS; account for most patients 
presenting with invasive fungal disease. However, a small number of patients present with 
invasive fungal disease (IFD) in the absence of HIV, or any other common secondary 
immunodeficiency. In this literature review, we explore the epidemiology and general 
management of invasive fungal diseases, while also reviewing the clinical and immunological 
characteristics of patients diagnosed with IFD, but without any secondary causes of 
immunosuppression. 
Definition of invasive fungal disease (IFD) 
Standard definitions for invasive fungal infections were published in 2002, by a consensus 
group of the European Organization for Research and Treatment of Cancer/Invasive Fungal 
Infections Cooperative Group (EORTC) and the National Institute of Allergy and Infectious 
Diseases Mycoses Study Group (MSG)(1).  
Invasive fungal disease defines a disease process caused by fungal infection, following the 
exclusion of an alternative etiology. This definition may include: (See tables 1-3 in Appendix 
at the end of Literature Review) 
Proven IFD: - this requires demonstration of fungal elements in diseased tissue, either directly 
(by culture or histology), or indirectly by use of assays that are highly specific for the infection 
being detected (e.g. presence of coccidiodal antibodies in CSF proves coccidioidomycosis; 
whereas the presence of cryptococcal capsular antigen in CSF proves disseminated 
cryptococcosis). 
Probable IFD: - this requires that a host factor, clinical features, and mycological evidence be 
present, as outlined in tables 2 and 3. 
Possible IFD: - this includes only those cases with the appropriate host factors and with enough 
clinical evidence consistent with IFD but for which there was no mycological support, as 
outlined in table 2. 
All the cases evaluated in this study were of proven IFD. 
Besides, chronic mucocutaneous candidiasis (CMC) is defined by recurrent or persistent 
infections affecting the nails, skin and oral and genital mucosae caused by Candida spp(2, 3). 
This entity was excluded in the study. 
Epidemiology of invasive fungal diseases 
The Leading International Fungal Education (LIFE) portal has been facilitating the estimation 
of the global burden of serious fungal infections within regions of the same country and 
between at-risk populations(4). Between 2013 and 2017, they estimated that more than 150 
million people have serious fungal diseases, which have a major impact on their lives or are 
fatal (4). There are about 3,000,000 cases of chronic pulmonary aspergillosis; 223,100 cases of 
cryptococcal meningitis complicating HIV/AIDs; 700,000 cases of invasive candidiasis; 
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500,000 cases of Pneumocystis jirovecii pneumonia; 250,000 cases of invasive aspergillosis; 
100,000 cases of disseminated histoplasmosis; over 10,000,000 cases of fungal asthma; and 
1,000,000 cases of fungal keratitis occurring annually (4-8). The HIV/AIDS pandemic, TB, 
COPD, asthma and the increasing incidence of cancers are the major drivers of fungal 
infections in both developed and developing countries globally(4, 6-9). 
Invasive candidiasis 
In 2016, the annual incidence of invasive candidiasis in the UK was estimated to be 5142 cases; 
with up to 40% mortality (10). In the US, Candida species were the third most frequently 
isolated organisms in a nationwide surveillance for nosocomial sepsis, with the crude mortality 
rates of up to 50%(11). In the LIFE portal, countries with high burdens of candida peritonitis 
included Mexico (5596; 4.98 per 100,000), Nigeria (2321; 1.5 per 100,000) and Spain (668; 
1.42 per 100,000)(4). The high morbidity and mortality of invasive candidiasis has been 
associated with the use of broad-spectrum antibiotics and corticosteroids, prolonged stay in 
ICUs, major intra-abdominal procedures, increased transplantations and cancers (10). Primary 
immune deficiencies (PIDs) associated with invasive candidiasis include 
abnormalities/deficiencies of CARD9, CD18, IL-12 and IL-17(12, 13). In these patients, 
PBMCs and neutrophils display impaired proinflammatory cytokine release and impaired 
killing function(12). 
Invasive aspergillosis (IA) 
Up to 81,927 cases of invasive aspergillosis had been observed by 2016; with the maximum 
number of cases in Vietnam (14,523/year) and the minimum in Trinidad and Tobago 
(8/year)(4). An annual incidence of 294 cases was estimated in Denmark, with 27 cases (9.1%) 
occurring in haematological malignancies; and 12 cases (4%) in transplant patients(14). COPD 
was the main driver for the burden and variability of IA in these cases(15). PID associated with 
IA include NADPH oxidase complex defect in phagocytes and granulocytes (leading to 
impaired respiratory burst activity and inability to kill fungal pathogens) and hyper IgE 
syndrome (HIES) (due to abnormal STAT-3 dependent epithelial immunity)(12). Egypt and 
Algeria reported cases of 10.7 and 7.1 per 100,000 persons annually, with the majority cases 
occurring in COPD. On the other hand, Nigeria and Kenya each had 0.6cases/100,000 persons 
with 10% of these in AML patients. In all cases, the mortality of IA has been reported to be 
ranging between 30-80%(4). 
Chronic pulmonary aspergillosis (CPA) (aspergilloma, chronic cavitary pulmonary 
aspergillosis and chronic fibrosing pulmonary aspergillosis) is thought to affect about 3 million 
people worldwide and, if untreated 80% of patients with CPA will die within 5 years (16). Prior 
TB is perhaps the most common underlying condition, with post-tuberculous cases probably 
representing 50% of the total cases. In the LIFE portal, an annual incidence of CPA was found 
to be 22cases/100,000persons for all the countries included. The highest incidence was in 
Russia (126.9/100,000), while the lowest incidence was in Canada (1.38/100,000 (4). 
Allergic bronchopulmonary aspergillosis (ABPA) is a common complication of asthma or 
cystic fibrosis (17, 18). These patients present with poorly controlled asthma, haemoptysis, 
fever and expectoration of mucus plugs. They display a positive skin test or high levels of 
Aspergillus specific IgE(17). Data from referrals to specialists in South Africa, New Zealand, 
Iran, Ireland, Saudi Arabia and China, translate to over 4.8 million cases of ABPA in adults 
(19). The prevalence of ABPA reflects adult asthma prevalence country by country, which has 
been estimated to be 2.5% in all the countries in the LIFE portal (4). 
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Cryptococcus neoformans  
Cryptococcus neoformans is the most common fungal infection in HIV, where cryptococcal 
meningo-encephalitis is an AIDS-defining illness (20). Park et al estimated that one million 
cases are reported each year in Sub-Saharan Africa, with more than 600 000 deaths/year in 
HIV-infected patients. Cryptococcal meningitis accounts for 20 to 25% of AIDS-related deaths 
in Africa(21). A study done in Cape Town showed cryptococcal meningitis accounting for 63% 
of all cases of meningitis in HIV patients, with a mortality of almost 50% despite treatment(22). 
Disseminated cryptococcal infection can cause clinical manifestations in the skin, ocular, soft 
tissue or bones and joints. Large cohort studies in London had 5% prevalence of cryptococcosis 
among HIV positive patients (23). 
Pneumocystis jirovecii (carinii)  
Pneumocystis jirovecii (carinii) is an obligate extracellular fungus which exclusively infects 
humans, causing a life-threatening form of interstitial pneumonia. HIV is the most common 
risk factor, where it causes an AIDS-defining pneumonia, commonly in patients with CD4 
counts <350 cells/µl. The global prevalence is thought to be >400,000 cases annually; with 
mortality ranging from 10-30% and even higher with delayed diagnosis(4, 8). The mortality 
has generally reduced in the era of highly active anti-retroviral therapy (HAART), but 
unacceptably high mortalities continue to be seen when diagnosis is not made in time, where 
drug shortages and stock outages limit access  to HAART, and in those who default on 
HAART(4, 8). In 40 published papers within the LIFE program, 133,487 cases have been 
estimated; with 75% occurring in Sub-Saharan Africa (4). In a systematic review by 
Wasserman et al, the pooled prevalence of PJP from all clinical settings in Sub-Sahara Africa 
was 15. 4%. This was associated with a case fatality rate of 18.8% (24). 
Deep dermatophytosis 
Deep dermatophytosis is characterized by the invasion of the dermis and hypodermis by 
dermatophytes, sometimes associated with lymph node, brain, digestive tract or bone 
involvement(25). While secondary causes of immunosuppression are the common risk factors, 
large global cohort studies identified 69 cases without any known immune deficiencies, with 
45 of these (65%) originating from North Africa(26). Twenty-four of these patients were from 
consanguineous families, with 19 familial cases from eight multiplex families. This suggests 
an autosomal recessive (AR) pattern of heredity to be a predisposing factor (26-29). Subsequent 
genetic studies have identified AR CARD9 deficiency among related family members with 
idiopathic deep dermatophytosis from North Africa (3, 13, 26). 
Dimorphic fungal infections 
Dimorphic fungal infections are endemic to certain geographical areas, including Histoplasma 
(Midwestern US), Coccidioides (South West US), and Paracoccidioides (Latin America)(30-
32). Disseminated histoplasmosis occurs in patients with immunodeficiency, mostly AIDS, 
and involves the reticulo-endothelial system and brain (12). A 5-year multicentre review of 70 
transplant patients (64 solid organ transplant  recipients and 6 hematopoietic stem cell 
transplant [HSCT] recipients) with endemic mycoses showed 52 with histoplasmosis (74%), 9 
with blastomycosis (12.8%), and 9 with coccidioidomycosis (12.8%) (33). Disseminated 
coccidioidomycosis involving the lungs, CNS and bones occurs in 55% of patients without 
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known risk factors. Genetic studies have revealed mutations affecting the interleukin-12/IFN-
g circuit and STAT-1 GOF (12). 
 
Diagnosis of invasive fungal disease 
The gold standard for the diagnosis of IFD is by culturing clinical specimens (tissue, sputum, 
urine, wound, or blood) to isolate the etiologic fungal agent(s), provided that the samples are 
from sterile sites such as blood, tissue or cerebrospinal fluid, in which fungal infection can be 
documented. Histopathology examination with special stains confirms fungal tissue 
involvement (34-36). 
Serological methods avail results sooner than culture. These may include skin tests and serum 
IgE for ABPA; cryptococcal antigen tests (CRAG) for cryptococcosis, fungal cell wall 
components e.g. galactomannan for Aspergillus spp. As per the European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID) guidelines, the combined detection of 
mannan and anti-mannan in blood/serum is considered specific (specificity up to 90% 
compared with blood culture=46%) for detection of Candida spp(36).  
The polymerase chain reaction (PCR) assay may be used for the diagnosis of systemic fungal 
infection in high-risk patients. Quantitative methods include PCR ELISA, with a sensitivity of 
about 83.3% and a specificity of about 91.7%; and real-time PCR, with the sensitivity about 
100% and a specificity about 97% (37, 38). 
Radiological evidence from X-rays and HRCT are useful adjuncts in the diagnoses. Pulmonary 
fungal infections such as aspergillosis, fusariosis, scedosporiosis or zygomycosis are 
characterized by central cavitation of pulmonary lesions, infiltration, pulmonary nodules, and 
halo or air-crescent signs (39, 40). 
 
Figure 1 showing Indian ink stain for C.neoformans in CSF; and CT chest showing lung 
aspergillomas(41). 
Management/treatment of patients with invasive fungal diseases 
Timely initiation of systemic antifungals is critical to prevent significant morbidity and/or 
mortality. Mortality increases by 20% for each 12-hour delay in antifungal therapy following 
a positive fungal culture(39). Besides, source control is a critical component of good anti-
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fungal stewardship, and may necessitate surgery debridement of infected tissues, or drainage 
of collections (39, 42).  
Commonly used antifungal agents include the azoles, polyenes,  allyamines and echinocandins. 
Various examples and their mechanisms of action are summarized in table 1 below(43). The 
choice depends on drug sensitivities, availability and co-morbidities. It may be necessary to 
monitor for drug toxicities and efficacy. Adjunctive therapy for co-morbidities is necessary, 
often with multi-disciplinary input. 
Table 1:- Antifungal drug classes, mechanisms of actions and common examples. 
ANTIFUNGAL DRUG 
CLASS 
MECHANISM OF 
ACTION 
DRUG NAMES 
Azoles Ergosterol synthesis 
inhibitors (cell membrane) 
Ketoconazole, fluconazole, 
itraconazole, voriconazole, 
posaconazole, ravuconazole 
Polyenes Fungal membrane-
disrupting agents (e.g. pores 
in membrane) 
Amphotericin B, nystatin 
Echinocandins Glucan synthesis inhibitors 
(cell wall) 
Caspofungin, anidulafungin, 
micafungin 
Allylamines Ergosterol synthesis 
inhibitors 
Terbinafine, butenafine 
Other Anti-mitotic (spindle 
disruption) 
Griseofulvin 
 
Primary treatment often requires parenteral administration for 4-6 weeks, or longer, in 
consultation with ID specialists. Patients would then need secondary/preventive therapy, 
usually orally, for a specified duration, which may be life-long in selected cases. For patients 
with treatable or manageable secondary immunodeficiency, restoration of immune function is 
crucial. This may be in the form of anti-retroviral therapies (ARVs) or immune therapies (34, 
44). 
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Literature Review 
Objectives of literature review 
This literature review sought to explore the clinical and immunological characteristics of 
adult patients with invasive fungal disease. This included mechanisms of antifungal 
immunity, primary and secondary immune defects leading to IFD, and site-specific disease 
susceptibilities. The scope of the search involved studies done locally and internationally. 
Literature search strategy 
Articles only in English were considered. PubMed and Google Scholar search engines were 
used to identify both full-text and abstract-type journals spanning through 1990 to 2017. The 
following key phrases were used for the search: “HIV-negative AND fungal diseases”, 
“invasive fungal infections AND HIV-negative”, “invasive fungal infections AND 
immunocompetent”, “primary immune deficiency AND invasive fungal infections”, 
“genetics AND invasive fungal infections”, “risk factors AND invasive fungal infections”, 
“clinical features AND invasive fungal infections’, “immunology AND fungal infections”, 
“management of invasive fungal infections”. The articles were saved directly into EndNote 
version X8 for citation and referencing management. These were then imported to HP 
notebook 2013. 
Results 
The table below shows the number of articles identified and selected from the databases. 
Articles identified and selected from the databases 
Database searched  Results** Used## 
PubMed 74 47 
Google scholar 46 18 
Total 120 65 
**Articles of potential interest identified from the two databases 
##Articles used after screening for relevance, duplication and citation permissions 
 
Antifungal immunology and known defects 
Introduction 
Fungi are ubiquitous in the environment and have co-evolved with human beings over several 
millennia. Due to constant exposure to these fungi, and with the ever-present risk of serious 
infections, humans have developed complex mechanisms for immune surveillance, pathogen 
recognition, processing and elimination; while maintaining auto-tolerance. The fungi have over 
the years also acquired increasingly complex evasion strategies against host immunity(43). On 
the balance, a host-fungal homeostasis exists(43). Recent findings of certain monogenic 
disorders among individuals with primary immune deficiencies, e.g. STAT1 GOF mutations, 
have shown such to have unusual susceptibilities to chronic and/or invasive fungal infections 
(3). These findings continue to elucidate interesting aspects of antifungal immune responses. 
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Antifungal Immunity 
Both innate and adaptive immune responses work in concert to eliminate or limit fungal 
infections. 
Figure 2 Key immune players in normal fungal immunity:- 
 
 
 
Abbreviations: ROS: Reactive oxygen species; DC: Dendritic cells; APECED: Autoimmune 
polyendocrinopathy candida and ectodermal dysplasia. 
Adapted from CMC review article by Peter and Onyango(43). 
 
The first line defence against fungal infections is the innate immunity; by way of physical 
barriers and cellular components. Intact skin and mucosal membranes deter fungal adhesion 
and entry. Therefore, any breaches in skin and mucosal integrity predisposes to fungal 
infections. Cells of the innate system e.g. Natural killer cells, neutrophils, dendritic cells (DC) 
and macrophages, bind components of fungal cell walls using pattern recognition receptors 
(PRR) and initiate killing by means of phagocytosis. C-type lectin receptors (CLR) such as 
Dectin-1 and Toll-like receptors (TLR) are particularly important for anti-fungal immunity. 
Recognition and ligation of fungal cell wall sugars and nucleic acids occurs by the 
evolutionarily conserved fungal pathogen associated molecular patterns (PAMPs); which 
activate TLR (TLR1-4, 6-9) and CLR signalling (45-47). This leads to the uptake, processing 
and presentation of the fungal components by antigen presenting cells (APCs), e.g. 
macrophages and dendritic cells. These APCs present the processed fungal antigens to naïve T 
cells, leading to their differentiation into Th-1 effector cells for fungal clearance. Due to their 
central role in fungal recognition and initiation of effective innate and adaptive immune 
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responses, individuals with certain genetic deficiencies of the PRRs e.g. CARD9 and Dectin-1 
are highly susceptible to fungemia, especially candida infections(45). 
Adaptive fungal immunity revolves around the balance between Th-17, Th-2 and Th-1 
effectors, driven by the DC responses to TLR and CLR signals provided by the fungus. The 
signalling activities of TLR and CLR induce MHC class II, co-stimulatory molecules, and 
cytokine expression by antigen-presenting cells that dictate T cell differentiation. Th1 and 
Th17 cells are the principal T helper subsets that contribute to protective immunity to several 
pathogenic fungi. Th-2 responses favour fungal infections, fungus-associated allergic 
responses, and disease relapse. Activated Th-1 cells produce effector cytokines e.g. IFN-
gamma and induces B-cell production of opsonizing antibodies (45, 48-50).  
MyD88-dependent signals, a major downstream component of the TLR pathway, are 
responsible for CD4+ T cell priming and trafficking to infected airways during respiratory 
fungal infection. For example, they mediate the stepwise differentiation of A. fumigatus-
specific CD4 T cells into IFN-γ-producing airway effector cells (51). IL-17 contributes to host 
resistance in oropharyngeal, cutaneous, and systemic fungemia, especially with C. albicans, 
and pulmonary infection with H. capsulatum. Th-17 cells are regulatory in fungal immunity by 
promoting Th-1 responses and restraining Th-2 responses (52, 53). These cells form part of the 
fungus-specific repertoire of memory cells.  
In the absence of Th-1 and Th-17 cells, then IL-22 (part of the AHR-IL-22 pathway), provides 
protection against candida at mucosal sites. IL-22 is produced by numerous activated innate 
lymphoid cells, as well as Th-1 and Th-17 cells. This protection is particularly prominent in 
the intestinal mucosa, against candida overgrowth (49, 50).  
Naturally acquired fungal infections do not induce protective antibodies against subsequent 
infections. Despite a growing medical need, no fungal vaccines are commercially available 
(54). One of the best ways to induce sterilizing immunity and achieve maximal protection is 
by using virulence-attenuated mutants. This has been under trials in experimental models of 
blastomycosis, histoplasmosis and coccidioidomycosis (55). Besides, vaccination with 
attenuated mutants induces antifungal memory CD8+ T cells that are maintained for at least 6 
months. These vaccine strains are however not likely to be safe in immunocompromised 
individuals. 
Figure 3 below, adapted from Romani et al(54), illustrates the interplay between innate and 
adaptive immune mechanisms activated by various fungal epitopes. 
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Figure 3: - Interplay between innate and adaptive immune mechanisms 
 
 
The knowledge gained from experimental vaccine models is crucial for the rational design of 
the next generation of  human vaccine putative candidates. Since the bulk of fungal protection 
centres on Th17 and Th1 cells, this is a novel paradigm for human vaccines (55-57). 
Essentially, these vaccines will confer protection via T-cell induced inflammatory cytokines 
e.g. IFN-γ, TNF, IL-17 and IL-22 that regulate the influx and killing functions of effector cells 
e.g. phagocytes; as well as by inducing memory antibodies that function by neutralizing 
virulence factors (e.g. adhesins), inhibiting fungal growth, and by stimulating direct killing, 
opsono-phagocytosis, and complement activation(58). 
Secondary immunodeficiency leading to invasive fungal diseases 
Secondary causes of immune deficiencies are associated with increased susceptibility and 
severity of various invasive fungal diseases. HIV/AIDS is the single most common secondary 
risk factor for invasive fungal infections; especially in high prevalence areas. Other secondary 
risk factors include solid and haematological cancers, chemotherapy, hematopoietic and solid 
organ transplantation, neutropenia, diabetes mellitus, prolonged corticosteroid use, prolonged 
stays in the ICU, and autoimmune diseases e.g. SLE and sarcoidosis.  
The table below gives a summary of spectrum of some of the invasive fungal infections, the 
associated secondary co-morbidities, and some identified genetic susceptibilities (42). A more 
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comprehensive discussion of the known genetic/monogenic disorders associated with invasive 
fungal infections follows in the subsequent section. 
Table 2:- Spectrum of invasive fungal infections, associated secondary co-morbidities and 
associated genetic susceptibilities 
SPECTRUM OF INVASIVE FUNGAL DISEASE, ASSOCIATED SECONDARY 
CO-MORBIDITIES AND GENETIC SUSCEPTIBILITIES 
Invasive candidiasis: - sepsis, 
meningitis, invasive organ 
disease 
HIV, DM 
Solid tumor 
HSCT 
Immunosuppressive Rx 
Major organ failure 
Severe combined 
immunodeficiency (SCID) 
Invasive aspergillosis: - 
hypersensitivity pneumonitis, 
meningoencephalitis 
Chronic steroid use 
DM 
HIV 
Mutations in the NADPH 
oxidase complex 
Cryptococcosis: - 
sepsis, meningitis, invasive 
solid organ disease 
HIV 
DM 
Immunosuppressive Rx 
HSCT 
Solid organ transplant 
IL-12R defect 
MonoMac, ADHIES, and 
HIGM syndromes 
Mucormycosis/zygomycosis: - 
pulmonary, rhinocerebral, 
disseminated 
HIV, HSCT, Solid organ 
transplant, Chronic steroid 
use, DM 
IL-12R defect 
Severe combined 
immunodeficiency (SCID) 
(DM=diabetes mellitus, HSCT=hematopoietic stem cell transplant, Rx=treatment, AD HIES=autosomal 
dominant hyper-IgE syndrome, HIGM=hyper-IgM syndrome) 
 
Cryptococcus neoformans, as previously noted, is the most common fungal infection in HIV, 
where cryptococcal meningo-encephalitis is an AIDS-defining illness. An epidemiological  
review of 11891 HIV-positive adults over a 3-year period with meningitis in Gauteng province, 
South Africa; showed the majority to have cryptococcal meningitis; associated with advanced 
HIV (59). 
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Figure 4: - Incidence of meningitis in Gauteng province, South Africa 
 
Cryptococcus gattii infection outbreak was first reported in 1999 in temperate British 
Columbia, Canada(60). A subsequent survey done between 1999-2007 showed up to 218 
reported cases with predominant respiratory and CNS syndromes at presentation; with a case 
fatality rate of 8.7%(61). Up to 73.7% of case-patients who died had an underlying secondary 
immunodeficiency; including HIV, diabetes, liver failure and solid organ transplant(61). The 
organism is now endemic in northern America with considerable public health 
consequences(62, 63). 
Surveillance studies done at Groote Schuur Hospital in Cape Town between 2008 to 2011 
identified Emmonsia species as an emerging new species of dimorphic fungi causing 
disseminated fungemia among patients with advanced HIV; especially those with CD4 counts 
of under 50cells/ml. More cases have since been described in other parts of South Africa, as 
well as in non-HIV patients (64, 65). 
In 2016, there were over 5000 cases of invasive candidiasis in the UK, with mortality rates of 
over 40% despite newer antifungals. This has been attributed to the use of broad-spectrum 
antibiotics and immunosuppressant agents, prolonged hospital and intensive care unit (ICU) 
stay, diabetes, nosocomial bacterial infection, recent surgery, pancreatitis, mechanical 
ventilation, total parenteral nutrition, use of medical devices such as central venous catheter 
and shunts, increased transplantation and more immune-compromising medical conditions 
such as malignancies. Abdominal surgery has been associated with increased risk of peritoneal 
candidiasis, as shown by data from Germany, Mexico and Nigeria (4). A retrospective hospital-
based study in Soweto, South Africa; showed Candida albicans to be the most common species 
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of invasive candidiasis. Others are C. tropicalis, C. glabrata and C. parapsilosis. Major 
predisposing conditions were abdominal surgery, HIV infection, trauma, diabetes mellitus and 
cancer(66). 
The highest risk populations for invasive aspergillosis comprise chronic granulomatous disease 
(especially TB, where aspergilloma are often found in old healed TB cavities and present with 
varying degrees of haemoptysis), prolonged neutropenia, HSCT and heart, lung and pancreas 
organ transplantation. In the UK, IA was found to complicate 9% of HSCT, 10% of, S.O.T.; 
0.6% of H.I.V.; 15% in haematological disease, and 1.3% of COPD admissions. Kenya, 
Tanzania and Nigeria each reported IA complicating 10% of A.M.L. and 10% of non-AML 
haematological patients, without data on COPD cases (4).  
Invasive histoplasmosis has been increasingly being reported in Africa, especially since the 
advent of HIV. Pulmonary histoplasmosis may be misdiagnosed as tuberculosis (TB). In the 
last six decades (1952–2017), 470 cases of histoplasmosis have been reported. HIV-infected 
patients accounted for 38% (178) of the cases. West Africa had the highest number of recorded 
cases with 179; the majority (162 cases) of which were caused by Histoplasma capsulatum 
var. dubuosii (Hcd). From the Southern African region, 150 cases have been reported, and the 
majority (119) was caused by H. capsulatum var. capsulatum (4). 
Known monogenic diseases associated with IFD. 
Defects of T-cell development and differentiation, phagocytic functions, and pathways 
involved in the innate recognition of pathogens and downstream signalling are associated with 
increased risk of fungal infections, the most common being candidiasis and aspergillosis(43). 
In South Africa, the bulk of these infections occur in the context of HIV/AIDS, as well as the 
aforementioned causes of secondary immune deficiency(43). Once these secondary risk factors 
have been excluded, a search for genetic factors should be made, especially where a family 
history exists(12).   
CD40L is expressed on activated T-cells and signals through NEMO/NF-κB to induce IL-12 
production(12). CD40L deficiency, also known as hyper-IgM syndrome, is inherited in an X-
linked recessive manner(67). Patients have impaired interaction between T-cells and antigen-
presenting cells (APCs)(68). Subsequently, they have low serum IgA & IgG; an elevated serum 
IgM; reduced IL-12 &IL-10, and are susceptible to opportunistic infections including PCP, 
cryptosporidiosis, and mycobacterial infections(12, 68). They are especially susceptible to 
disseminated histoplasmosis(69). 
GATA2 is a member of the GATA family of transcription factors. It is widely expressed on 
early hematopoietic progenitors, megakaryocytes and in mast cell lineages(70). Patients with 
haploid insufficiency of the hematopoietic transcription factor GATA2 are recognized by a 
syndrome of monocytopenia with susceptibility to non-tuberculous mycobacterial (NTM) 
infections, often termed “MonoMAC”(71). These patients display monocytopenia; NK, B cell 
&CD4 lymphocytopenia, and neutropenia(71). A cohort of 57 patients with GATA2 mutations 
evaluated in the US had 16% with serious fungal infections, including invasive aspergillosis, 
disseminated histoplasmosis and recalcitrant mucosal candidiasis(72). Other significant 
findings in these patients include congenital lymphedema, pulmonary alveolar proteinosis, and 
predisposition to myelodysplastic syndrome or acute myeloid leukaemia(70). The table below 
is an adaptation from the excellent review by Lanternier et al, which highlights the main known 
genetic defects underlying some invasive mycoses (12). 
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Table 3: - Genetic defects underlying IFD 
MONOGENIC DISORDERS ASSOCIATED WITH INVASIVE FUNGAL 
DISEASES 
 
GENETIC 
DEFECT 
INHERITANCE IMMUNOLOGICAL 
PHENOTYPE 
FUNGAL 
INFECTION 
CLINICAL AND 
ASSOCIATED 
FEATURES 
CD40 
Ligand 
deficiency 
(Hyper 
IgM 
syndrome) 
X-linked 
recessive 
Low s-IgA & IgG; 
elevated serum IgM; 
reduced IL-12 &IL-
10 
Histoplasmosis Disseminated 
histoplasmosis 
with esophageal 
ulcers, 
lymphadenitis, 
pulmonary, and 
bone marrow 
involvement, 
CGD 
GATA2 
Deficiency 
Heterozygous 
familial/sporadic 
with multiple hit 
sites 
Monocytopenia, NK, 
B cell &CD4 
lymphocytopenia, 
and neutropenia 
Histoplasmosis 
Aspergillosis 
Candidemia 
Disseminated 
histoplasmosis & 
aspergillosis, 
Recalcitrant 
candidemia, 
MonoMac, MDS, 
AML, viral 
infections 
IL12Rβ1 
Deficiency 
Autosomal 
recessive 
No response to IL-
12, IL-17 and IL-23. 
Impaired IFN-γ 
production by T and 
NK cells 
Candida 
Histoplasma 
Coccidioides 
Paracoccidioides 
MSMD, non-
typhoidal 
salmonellosis of 
unusual severity, 
Klebsiella, 
Nocardia, 
Leishmania, 
Klebsiella, 
Nocardia, 
Leishmania 
IFNγ 
Receptor 
Deficiency 
Autosomal 
recessive; or 
Autosomal 
dominant 
IFNγR1 or R2 
deficiency, both 
quantitative and 
qualitative 
Histoplasmosis 
Candidemia 
Coccidioidomycosis 
Disseminated 
fungemia, 
listeriosis, CMV, 
VZV, NTM 
STAT1  AD GOF 
mutation 
Decreased IL-17-
producing 
T-cells decreased 
switched 
memory B-cells 
Candidiasis (CMC) 
Histoplasmosis 
Cryptococcus 
Coccicioides 
Aneurysm, 
autoimmune 
diseases, 
endocrine 
diseases, 
susceptibility to 
mycobacterial, 
viral, and bacterial 
infections 
STAT3 AD LOF Increased serum IgE, 
eosinophilia 
decreased 
IL-17-producing T-
cells 
Aspergillosis 
 
Hyper IgE synd, 
disseminated 
fungemia, 
Eczema, scoliosis, 
pneumatocele, 
hyperextensibility, 
dysmorphic 
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facial features, 
retention of 
primary teeth 
CARD9 AR Decreased IL-17-
producing 
T-cells, impairment 
of Candida killing by 
neutrophils 
Candidemia Dermatophytes, 
candida brain 
abscess 
(CGD=chronic granulomatous disease, GATA2= a zinc finger transcription factor, MDS=myelodysplastic 
syndrome, AML=acute myeloid leukaemia, MSMD=mendelian susceptibility to mycobacterial diseases, 
CMV=cytomegalovirus, VZV=varicella zoster virus, NTM=non-tuberculous mycobacteria, STAT=signal 
transducer and activator of transcription, AD LOF=autosomal dominant loss of function gene, 
CARD9=caspase recruitment domain-containing protein 9, AR=autosomal recessive) 
 
Inborn errors of immunity associated with impaired Th-17-mediated immunity are many. For 
example, in STAT1 AD GOF mutations, there is impaired dephosphorylation of STAT1, 
leading to a persistent ‘on’ switch after stimulation with IFN-γ, IFN-α/β, and IL-27(3). This, 
in turn, inhibits TH-17 cells and IL-17A, IL-17F and IL-22 production and leads to increased 
fungal susceptibility(3). This is thus associated with both minor and invasive forms of 
Candidiasis (CMC), Histoplasmosis, Cryptococcosis and Coccicioides infections(26). STAT3 
AD LOF mutations have impaired RORγt induction in response to IL-1β, IL-6, and IL-23, 
causing severe deficiency of IL-17-producing effector cells(73). These are associated with 
increased serum IgE levels (hyper IgE syndrome), eczema, disseminated Aspergillosis, 
recurrent staphylococcal cold abscesses, pneumonia, joint hyperextensibility, skeletal 
abnormalities and pathological fractures, delayed dental deciduation, coronary artery 
aneurysms and several congenital dysmorphic features(73). CARD9 is a member of the CARD 
protein family, which is defined by the presence of a characteristic caspase-associated 
recruitment domain (CARD)(74). CARD9 mediates signals from pattern recognition receptors 
(PRRs), e.g. Dectin 1; to downstream signalling pathways, thus activating appropriate pro- and 
anti-inflammatory pathways to induce effective clearance of infections(74). CARD9 AR 
deficiency has been associated to both chronic mucocutaneous and disseminated candidiasis, 
including candida brain abscesses; as well as inflammatory diseases e.g., Ankylosing 
spondylitis and inflammatory bowel disease(12, 13, 74). 
Figure 5 below serves to highlight some of the known molecular defects underlying invasive 
fungal diseases(75). 
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Figure 5:-Molecular defects underlying invasive fungal disease 
 
 
(CARD9= caspase recruitment domain-containing protein 9, STAT3= signal transducer and activator of 
transcription) 
Site specific disease susceptibilities 
Certain monogenic abnormalities are associated with site-specific invasive fungal diseases. 
The table below is an adaptation from Lanternier et al, who looked at various examples of such 
site-specific invasive fungal diseases, with their corresponding primary immune aberrations.  
Table 4:- Site-specific fungal disease and associated monogenic disorders 
INVASIVE 
FUNGUS 
SITE OF 
INFECTION 
MONOGENIC 
DISORDER(S) 
CLINICAL 
ASSOCIATIONS 
Invasive aspergillosis Pulmonary disease 
 
X-linked CYBB 
mutations 
AD HIES (STAT3 
def), SCN, CD18 
def 
AD GATA2 
deficiency 
CGD, 
pneumatocysts, 
recurrent bacterial & 
mycobacterial 
infections 
Invasive candidiasis Cerebrovascular 
disease 
Mucocutaneous 
disease 
AR CD18 
deficiency 
CARD9 deficiency 
Candida meningitis, 
CGD, CMC 
Deep 
dermatophytosis 
Invasion of the 
dermis 
and hypodermis 
CARD9 deficiency Idiopathic deep 
dermatophytosis 
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Invasive 
cryptococcosis 
Cerebrovascular 
disease 
Autoantibodies 
against GM-CSF or 
against IFN-γ 
X-linked CD40L 
deficiency 
AD GATA2 
deficiency 
Meningo-
encephalitis 
disseminated NTM 
Pneumocystosis  Pulmonary disease X-linked CD40L 
def 
SCID, AR MHC 
class II deficiency, 
AR DOCK8 
deficiency 
X-linked NF-kB 
Essential Modulator 
(NEMO) deficiency 
AR CARD11 
deficiency 
Pneumocystis 
jirovecii pneumonia 
Disseminated 
histoplasmosis 
Reticulo-endothelial 
system, and 
brain 
Interleukin-12Rb1 
deficiency, IFN-gR1 
deficiency, STAT1 
GOF mutation 
Severe infections of 
lymph nodes, liver, 
spleen, mucosae, 
bone marrow and 
brain 
Disseminated 
coccidioidomycosis 
Pulmonary and 
cerebrovascular 
disease 
Interleukin-12Rb1 
deficiency, IFN-gR1 
deficiency, STAT1 
GOF mutation 
Severe infections of 
lungs, CNS and 
bones 
(CGD=chronic granulomatous disease, AD HIES=autosomal dominant hyper-IgE syndrome, CARD=caspase 
recruitment domain-containing protein, AR=autosomal recessive, CMC=chronic mucocutaneous candidiasis, 
MHC=major histocompatibility complex) 
 
Patients with the pulmonary form of invasive aspergillosis have an NADPH oxidase complex 
defect in phagocytes, mostly due to X-linked CYBB mutations(76). This leads to defects in 
reactive oxygen species production and effectively, impaired respiratory burst function 
necessary for effective fungal killing by effector cells(77). In CARD9 deficiency, patients have 
increased susceptibility for disseminated candida (including candida meningitis) and deep 
dermatophytosis due to impaired production of pro-inflammatory cytokines, especially 
IL17(74). Cases of disseminated coccidioidomycosis involving the lungs, CNS and bones; and 
disseminated histoplasmosis involving the lymph nodes, liver, spleen, mucosae, bone marrow 
and brain; have been described in patients with STAT1 GOF mutations; GATA2, DOCK8, XL 
CD40L deficiencies(12). In these patients, there’s impaired pro-inflammatory signalling 
related to IF deficiencies in the IFN -gamma/ interleukin-12 axis(12). 
Polygenic susceptibility to IFD 
Complex interplay between gene polymorphisms and genetic errors have been implicated in 
an immunodeficiency phenotype and an increased incidence of opportunistic fungal diseases. 
These genetic variations, known as single-nucleotide polymorphisms (SNPs), have been 
proposed to affect both innate and adaptive immunity to IFD such as Candida and 
Aspergillus(78). For example, IFN-γ 874T>A polymorphism as a single SNP or as a combined 
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deficiency with an SNP in Toll-the like receptor (TLR)-4 gene (1063A>G) has shown a trend 
to cause increased susceptibility to invasive aspergillosis(79). SNPs affecting IL-10 and IL-
12B genes are significantly associated with persistent candidemia, owing to decreased 
proinflammatory cytokine concentrations(80). 
Future areas of research 
Whereas cases of invasive fungal infections abound in many population groups, the vast 
majority of the cases are found in the context of secondary immune deficiency. The bulk of 
research into these infections has been done outside of Africa. African populations have 
marked ethnic and genetic diversity. This is an area of potential active studies, in order to 
unravel possible genetic aberrations that may predispose to chronic or recurrent severe 
infections.  
Conclusion 
Isolated cases of monogenic disorders predisposing to recurrent fungal and other infections, 
have also recently been published in  Sub-Saharan Africa (43). The possibility of new 
discoveries in the African populations, of novel genes and their variants as the key determinants 
of recurrent or severe disease, should inspire more active scientific interest in the various 
African populations. This is especially important for invasive fungal diseases, as these are 
associated with significant morbidity and mortality. This case series serves as a starting point 
in response to this need. 
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APPENDIX 
 
Table 1 
Criteria for proven invasive fungal disease except for endemic mycoses 
Analysis 
and 
specimen 
Moulds Yeasts 
 
Microscopic 
analysis: 
sterile 
material 
Histopathologic, cytopathologic, 
or direct microscopic 
examinationbof a specimen 
obtained by needle aspiration or 
biopsy in which hyphae or 
melanized yeast-like forms are 
seen accompanied by evidence 
of associated tissue damage 
Histopathologic, cytopathologic, or direct 
microscopic examinationb of a specimen 
obtained by needle aspiration or biopsy 
from a normally sterile site (other than 
mucous membranes) showing yeast 
cells—for example, Cryptococcus species 
indicated by encapsulated budding yeasts 
or Candida species showing pseudo 
hyphae or true hyphaec 
 
Culture 
  
 Sterile 
material 
Recovery of a mould or “black 
yeast” by culture of a specimen 
obtained by a sterile procedure 
from a normally sterile and 
clinically or radiologically 
abnormal site consistent with an 
infectious disease process, 
excluding bronchoalveolar 
lavage fluid, a cranial sinus 
cavity specimen, and urine 
Recovery of a yeast by culture of a 
sample obtained by a sterile procedure 
(including a freshly placed [<24 h ago] 
drain) from a normally sterile site 
showing a clinical or radiological 
abnormality consistent with an infectious 
disease process 
 
 Blood Blood culture that yields a 
mould (e.g., Fusarium species) 
in the context of a compatible 
infectious disease process 
Blood culture that yields yeast 
(e.g., Cryptococcus or Candida species) 
or yeast-like fungi 
(e.g., Trichosporon species) 
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Analysis 
and 
specimen 
Moulds Yeasts 
 
Serological 
analysis: 
CSF 
Not applicable Cryptococcal antigen in CSF indicates 
disseminated cryptococcosis 
 
aIf culture is available, append the identification at the genus or species level from the 
culture results. bTissue and cells submitted for histopathologic or cytopathologic studies 
should be stained by Grocott-Gomorri methenamine silver stain or by periodic acid Schiff 
stain, to facilitate inspection of fungal structures. Whenever possible, wet mounts of 
specimens from foci related to invasive fungal disease should be stained with a fluorescent 
dye (e.g., calcofluor or blankophor). cCandida, Trichosporon, and yeast-
like Geotrichum species and Blastoschizomyces capitatus may also form pseudohyphae or 
true hyphae. dRecovery of Aspergillus species from blood cultures invariably represents 
contamination. 
 
Table 2 
Criteria for probable invasive fungal disease except for endemic mycoses 
Host factorsa 
Recent history of neutropenia (<0.5 × 109 neutrophils/L [<500 neutrophils/mm3] for >10 
days) temporally related to the onset of fungal disease 
Receipt of an allogeneic stem cell transplant 
Prolonged use of corticosteroids (excluding among patients with allergic 
bronchopulmonary aspergillosis) at a mean minimum dose of 0.3 mg/kg/day of prednisone 
equivalent for >3 weeks 
Treatment with other recognized T cell immunosuppressants, such as cyclosporine, TNF-
α blockers, specific monoclonal antibodies (such as alemtuzumab), or nucleoside analogues 
during the past 90 days 
Inherited severe immunodeficiency (such as chronic granulomatous disease or severe 
combined immunodeficiency) 
Clinical criteria 
 Lower respiratory tract fungal diseasec 
 The presence of 1 of the following 3 signs on CT: 
   Dense, well-circumscribed lesions(s) with or without a halo sign 
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   Air-crescent sign 
   Cavity 
  
Tracheobronchitis 
  Tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen on 
bronchoscopic analysis 
 Sinonasal infection 
  Imaging showing sinusitis plus at least 1 of the following 3 signs: 
   Acute localized pain (including pain radiating to the eye) 
   Nasal ulcer with black eschar 
   Extension from the paranasal sinus across bony barriers, including into the orbit 
 CNS infection 
  1 of the following 2 signs: 
   Focal lesions on imaging 
   Meningeal enhancement on MRI or CT 
 Disseminated candidiasis 
  At least 1 of the following 2 entities after an episode of candidemia within the 
previous 2 weeks: 
   Small, target-like abscesses (bull's-eye lesions) in liver or spleen 
   Progressive retinal exudates on ophthalmologic examination 
Mycological criteria 
 Direct test (cytology, direct microscopy, or culture) 
  Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate 
samples, indicated by 1 of the following: 
   Presence of fungal elements indicating a mold 
   Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, 
or Scedosporium species) 
 Indirect tests (detection of antigen or cell-wall constituents)e 
  Aspergillosis 
   Galactomannan antigen detected in plasma, serum, bronchoalveolar lavage fluid, or 
CSF 
  Invasive fungal disease other than cryptococcosis and zygomycoses 
   β-d-glucan detected in serum 
NOTE. Probable IFD requires the presence of a host factor, a clinical criterion, and a 
mycological criterion. Cases that meet the criteria for a host factor and a clinical criterion but 
for which mycological criteria are absent are considered possible IFD. 
aHost factors are not synonymous with risk factors and are characteristics by which 
individuals predisposed to invasive fungal diseases can be recognized. They are intended 
primarily to apply to patients given treatment for malignant disease and to recipients of 
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allogeneic hematopoietic stem cell and solid-organ transplants. These host factors are also 
applicable to patients who receive corticosteroids and other T cell suppressants as well as to 
patients with primary immunodeficiencies. 
bMust be consistent with the mycological findings, if any, and must be temporally related to 
current episode. 
cEvery reasonable attempt should be made to exclude an alternative etiology. 
dThe presence of signs and symptoms consistent with sepsis syndrome indicates acute 
disseminated disease, whereas their absence denotes chronic disseminated disease. 
e These tests are primarily applicable to aspergillosis and candidiasis and are not useful in 
diagnosing infections due to Cryptococcus species or Zygomycetes (e.g., Rhizopus, Mucor, 
or Absidia species). Detection of nucleic acid is not included, because there are as yet no 
validated or standardized methods. 
 
Table 3 
Criteria for the diagnosis of endemic mycoses 
Diagnosis and criteria 
Proven endemic mycosis 
 In a host with an illness consistent with an endemic mycosis, 1 of the following: 
  Recovery in culture from a specimen obtained from the affected site or from blood 
  Histopathologic or direct microscopic demonstration of appropriate morphologic 
forms with a truly distinctive appearance characteristic of dimorphic fungi, such 
as Coccidioides species spherules, Blastomyces dermatitidis (thick-walled broad-based 
budding yeasts), Paracoccidioides brasiliensis (multiple budding yeast cells), and, in the 
case of histoplasmosis, the presence of characteristic intracellular yeast forms in a 
phagocyte in a peripheral blood smear or in tissue macrophages 
  For coccidioidomycosis, demonstration of coccidioidal antibody in CSF, or a 2-
dilution rise measured in 2 consecutive blood samples tested concurrently in the setting of 
an ongoing infectious disease process 
  For paracoccidioidomycosis, demonstration in 2 consecutive serum samples of a 
precipitin band to paracoccidioidin concurrently in the setting of an ongoing infectious 
disease process 
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Diagnosis and criteria 
Probable endemic mycosis 
 Presence of a host factor, including but not limited to those specified in table 2, plus a 
clinical picture consistent with endemic mycosis and mycological evidence, such as a 
positive Histoplasma antigen test result from urine, blood, or CSF 
NOTE. Endemic mycoses include histoplasmosis, blastomycosis, coccidioidomycosis, 
paracoccidioidomycosis, sporotrichosis, and infection due to Penicillium marneffei. Onset 
within 3 months after presentation defines a primary pulmonary infection. There is no 
category of possible endemic mycosis, as such, because neither host factors nor clinical 
features are sufficiently specific; such cases are considered to be of value too limited to 
include in clinical trials, epidemiological studies, or evaluations of diagnostic tests. 
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Invasive Fungal Disease in HIV-negative South African Patients – functional immune 
work-up in search of primary immunodeficiency 
1Onyango Vonwicks Czelestakov, 1Kathryn Manning, 2Steven Makatsa Mohau, 2Claire 
Hoving, 2Wendy Burgers, 3Sipho Dlamini, 4Jonny Peter 
Abstract 
Background 
The majority of invasive fungal disease in South African hospitals is HIV-related or associated 
with another secondary immunodeficiency e.g. haematopoietic stem cell transplant. After 
excluding secondary immunodeficiency, a detailed immune work-up can lead to a diagnosis of  
primary immunodeficiency. 
Objective 
To detail an appropriate step-wise immunological work-up for a series of patients with invasive 
fungal diseases and possible underlying primary immune deficiency. 
Methods 
Detailed review of all culture- or histologically confirmed cases of invasive fungal disease 
(IFD) at Groote Schuur Hospital between 2007-2017. Step-wise immunological work-up of  
IFD patients with no secondary immunodeficiency. Clinical characteristics and step-wise 
immunological profiles were evaluated. 
Results 
Sixty-seven adults with IFD were identified; 72% (48/67) were HIV-related. 8/19 HIV-
negative cases were either deceased (4) or lost-to-follow-up (4). Work-up of the remaining 11 
cases found five with non-HIV secondary immunodeficiencies (Lupus, liver transplant, end-
stage renal failure and haematological malignancy). A primary immunodeficiency was 
suspected in six cases, but 1 case of cutaneous sporotrichosis was excluded; with five cases (4 
with disseminated Cryptococcus neoformans and 1 with cerebral aspergillosis) undergoing 
detailed immune work-up. A case of idiopathic CD4 lymphopenia was diagnosed; but all other 
cases had no evidence of neutrophil or a cell-mediated immune defect; including investigations 
of naïve and memory T-cell subsets and cytokine responses to PHA and candida. All cases 
were noted to have low baseline vaccine responses and Vitamin D deficiency. 
Conclusion 
Invasive fungal disease is predominantly associated with HIV and secondary 
immunodeficiency in South Africa. Known primary immunodeficiencies can be identified with 
basic immune work-up; but no obvious functional immune defect is evident in the majority of 
these cases.  
Key words: invasive fungal disease, primary immune deficiency, secondary immune 
suppression 
Word count: 3633 
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Introduction 
Innate and adaptive immune mechanisms often restrict fungal infections to the skin and 
mucosa. Invasive fungal infections occur whenever there is failure of these immune 
mechanisms to contain invading fungal elements; often leading to severe and disseminated 
disease. The main causes of invasive fungal disease (IFD) are secondary immunodeficiency; 
particularly HIV/AIDS. Disseminated mycoses are AIDS-defining opportunistic illnesses. 
Cryptococcal meningo-encephalitis is the most common fungal infection in HIV[1]. Other 
causes of secondary immunodeficiency associated with severe, recurrent or persistent fungal 
infections include diabetes, cancers, chemotherapy, bone marrow and solid organ transplant 
and immunosuppressive drug regimens, as well as auto-immune diseases, e.g. . systemic lupus 
erythromatosus [SLE][2]. 
A small number of patients present with IFD in the absence of HIV, or any other common 
secondary immunodeficiency. These patients display widely variable clinical manifestations 
of IFD, with different degrees of morbidity and mortality. Whether these patients have an 
undiagnosed secondary immune deficiency, or an already described primary 
immunodeficiency, or novel genetic mutations with an increased susceptibility to invasive 
fungal disease, remains unanswered. Several primary immune deficiencies have been described 
in patients with IFD including: homozygous mutations in caspase recruitment domain-
containing protein 9 (CARD9) with deep dermatophytosis of central nervous system (CNS) 
and gastrointestinal (GIT) system[3]; isolated CD4 lymphopenia[4]; severe congenital 
neutropenia; leucocyte adhesion deficiency, and inborn errors of the phagocytic respiratory 
burst activity, necessary for fungal killing. Endemic mycoses have also been linked to 
congenital errors of IFN-/IL-12 signalling pathway and acquired auto-antibodies to both IFN-
 and GM-CSF[5]. 
To date, we have not found any African studies that have conducted in-depth clinical and 
immunological assessments in HIV-negative cohorts of IFD without an obvious underlying 
secondary immunodeficiency. This case series is the result of our study to systematically 
review the immunological basis of cases of microbiological or histology-proven IFD in adults 
(>18 years) diagnosed at Groote Schuur Hospital - a tertiary hospital in Cape Town, South 
Africa, between 2007-2017. To the best of our knowledge, this is the first such study conducted 
on a series of adult African patients. 
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Methods 
Work-up of invasive fungal disease: Secondary to primary immunodeficiency 
The infectious diseases clinic maintains an electronic database of all patients treated for IFD at 
Groote Schuur hospital, thereby allowing us to identify all patients with culture and/or 
histologically proven IFD treated between 31st August 2007 to 30th September 2017. Adult 
patients (>18 years) from this database were systematically reviewed for confirmed secondary 
immunodeficiency e.g. HIV status. All patients without a known secondary immunodeficiency 
were contacted by phone or community health worker. The study was approved by the 
University of Cape Town Human Research Ethics Committee (HREC 010/2017). Traceable 
patients were investigated for a previously unidentified secondary immunodeficiency; 
followed by a detailed immune work-up (see online appendix for details of laboratory and 
immunological work-up) 
Non-routine flow cytometry investigations 
Peripheral blood mononuclear cells (PBMCs) from each patient was subjected to cytokine 
stimulation assays using mycobacterium tuberculin (MTB) lysate and mitogens 
phytohemagglutinin (PHA) and phorbol myristate acetate (PMA). These were then run by flow 
cytometry. 4 healthy control samples were included, while non-stimulated blood was used as 
negative control. Analyses included T cell subsets, cytokines, and T cell memory phenotype. 
Results 
Figure 1 shows a flow diagram of the 84 IFD cases in the electronic database. Of these, 79.7% 
(67/84) were adults (≥18 years); and 72% (48/84) were HIV-positive. Of the remaining 19 
HIV-negative patients; four were deceased and four were not traceable. We investigated 13% 
(11/84) patients in further detail and found that five had a previously unidentified secondary 
immunodeficiency including: two had systemic lupus erythematosus (SLE), one had end stage 
renal disease (ESRD), one had acute lymphoblastic leukaemia (ALL), and one was a post liver 
transplant patient on immunosuppressants. Hence, only six patients were considered to warrant 
detailed immunological work-up for a possible underlying primary immunodeficiency. One 
case of cutaneous sporotrichosis was excluded from this cases series, and further detailed case 
vignettes and laboratory data are presented on five cases. 
(See appendix 1, online supplement, showing the infectious work-up at the time of IFD 
presentation.) 
 
 
 
 
 
 
 
 
33 
 
 
Figure 1: Flow chart showing patient enrolment  
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HIV Positive2 
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KEY 2 
1: Diagnosis of IFD made on fungal cultures (blood and tissue) and/or histology 
2: Diagnosis of HIV made on ELISA tests 
3: Patients already deceased before study enrolment  
4: Patients not traceable  
5: Patients found to have secondary immune deficiency on further review  
KEY 1 
SLE: Systemic lupus erythromatosus 
ESRD: End-stage renal disease 
ALL: Acute lymphoblastic leukaemia 
34 
 
Clinical case vignettes 
Case 1 
A 49-year-old male security guard, who presented to hospital with 4-months of recurrent 
headaches and 3rd, 4th, and 6th right-sided cranial nerves palsies. He had no relevant past 
medical history. Family history included deceased father and mother from pulmonary TB and 
suspected meningitis respectively; his teenage son also has a pulmonary TB history. MRI brain 
showed a left cavernous sinus mass, that progressed to a left temporal lobe abscess 
communicating with the para-cavernous space (See the corresponding images in Figure 2). 
The abscess was debrided and drained, with both histology and culture showing Aspergillus 
fumigatus. He was treated with induction intravenous voriconazole (2 weeks), with 
maintenance oral voriconazole. An incidental diagnosis of neurosyphilis was also made and 
treated with intravenous penicillin. He has had no further IFD in the subsequent four years, and 
only a mild residual 6th cranial nerve paresis. 
 Case 2 
A 68-year old male pensioner, who presented to hospital with a 3-month history of dysphagia, 
hoarse voice and weight loss. His past medical history included recurrent tinea corporis and 
herpetic shingles in puberty; and hypertension. Family history includes a grandchild who is 
asthmatic, and another with eczema. Chest x-ray and chest CT scans showed a well-
circumscribed mass in his left upper lobe (See the corresponding images in Figure 2). He had 
partial pneumonectomy of the left upper lobe, and the culture and histopathology of the tissue 
confirmed Cryptococcus neoformans. The peri-bronchial lymph node tissue was also positive 
for M. tuberculosis on histology. Given his repeatedly negative serum CLAT, a clinical 
decision was made not to treat him with antifungals following the operation. He was fully 
treated for the TB, and mild anaemia of chronic illness. He has had no further IFD in the 
subsequent four years. 
Case 3 
A 36-year old female call centre employee, who presented with a 3-week history of left breast 
swelling with inflammatory features. This was found to be an abscess (See the corresponding 
images in Figure 2). She had incision and drainage with debridement of the infected breast, 
and tissue samples confirmed Cryptococcus neoformans on culture and histopathology. Her 
serum CLAT was positive.  Moderate eczema was her only comorbidity; family history 
includes atopy, and her 4-year old son with recurrent tinea corporis. She was treated with 8 
weeks of intravenous Amphotericin B, and subsequently maintained on oral Fluconazole. 
During longstanding azole therapy, she developed a normocytic anaemia, leukopenia 
(3.0x109/L), neutropenia(1.4x109/L) and lymphopenia(0.9x109/L), which have resolved 
without treatment on follow-up. She has had no further IFD in the subsequent three years.  
Case 4 
A 41-year old male casual labourer; whom presented with a 3-month history of right breast 
swelling and recurrent headaches, with no constitutional symptoms and normal neurological 
exam. His past medical history includes recurrent tinea corporis in childhood; and 
polysubstance abuse (smoking of methamphetamine, mandrax and tobacco). Family history 
includes a brother who had recurrent tinea corporis, and a daughter with eczema and asthma. 
He was found to have a persistent low CD4 count of 218 cells/µl, absolute lymphopenia, with 
positive serum and CSF CLAT. He had a normal chest x-ray and brain CT scan. The breast 
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swelling was an abscess, and he had diagnostic aspiration and subsequent incision and drainage 
with debridement of infected tissue. All these confirmed Cryptococcus neoformans on culture 
and histopathology. He was started on intravenous Amphotericin B but left the hospital against 
medical advice after 10 days of treatment. He has since been on maintenance high dose oral 
fluconazole. His absolute lymphopenia resolved on follow-up blood tests.  He has remained 
stable during two years of follow-up, but his CD4 counts have remained <300 cells/µl.  
Case 5 
A 44-year old male laboratory technician; whom presented in 2007 with a 2-week history of 
cough with haemoptysis, and no constitutional symptoms. His past medical history included 
chronic tobacco smoking and a spontaneous pneumothorax at age 39. Family history included 
a sister who died of unknown cause at age 2-3 years; and a daughter with penicillin allergy. TB 
work up was negative. His CXR and CT chest showed a well-circumscribed mass in his right 
lung hilar (See the corresponding images in Figure 2). He had excision of the lung mass (partial 
pneumonectomy), with samples confirming Cryptococcus neoformans on culture and 
histopathology. He was treated with 6 weeks of intravenous Amphotericin B and subsequently 
has been on long term oral fluconazole. He developed focal seizures in 2012, and a CT brain 
showed cerebral parenchymal lesions, which have remained static on serial scans. His serum 
and CSF CLAT were both positive then. His cerebral lesions have been presumed to be 
cryptococcomas and deemed to be the cause of his seizures; and he’s on long-term antiepileptic 
therapy, plus ongoing oral fluconazole. He had also been managed with tapering doses of oral 
steroids for about 2 years following the diagnosis of the cerebral lesions; but this was stopped 
when he developed avascular necrosis of the left femur head, with total hip replacement in 
2014. Now, age 55, he is stable, with subsequent CSF and serum CLAT negative on serial 
reviews; and is on regular follow up at the ID clinic.  
Figure 2 below shows a collage of the image series for the case vignettes 
(See appendix 2, online supplement, for comprehensive case vignettes with expanded image 
series.) 
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Figure 2: Collage of Image series 
   
   
   
     
KEY: IMAGING STUDIES OF THE VARIOUS PATIENTS 
Row 1: Case 1 (L) MRI brain showing enhancing left cavernous sinus mass (black arrow) ;(R) CT showing 
near complete resolution- normal left cavernous sinus with mild residual expansion only (white arrow). 
Row 2: Case 2 (L)CXR showing spiculated left upper lobe mass (black arrow) ;(R) CXR post excision of 
the left upper lobe mass (black arrow-head), with loss of lung volume (double black arrows) 
Row 3: Case 3 (L) Mammogram showing increased architectural distortion and density in the upper outer 
quadrant (black arrow-heads). Sonography confirmed a sinus with a linear fluid collection with reactive 
lymph node. No masses. Case 5 (R) CXR done in 2012 following right partial pneumonectomy with volume 
loss (black arrow) 
Row 4: Case 5 (L) CT brain in 2012 and (R) in 2018 showing unchanged cerebral parenchymal lesions 
with peripheral enhancement (black arrow-heads) 
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Patient Clinical Characteristics 
At the time of IFD diagnosis, two patients had no significant medical comorbidities. However, 
one patient (case 2) had hypertension, one (case 3) had eczema, and one (case 5) a history of 
active polysubstance abuse. All the diagnoses of IFD were made based on fungal culture and/or 
histopathology of body fluids and/or tissue specimens; 80% (4/5) of cases had invasive 
cryptococcal disease, caused by Cryptococcus neoformans. Sites of IFD included: i) Case 1 
presented with intracerebral abscesses secondary to aspergillosis (organism was Aspergillus 
fumigatus); ii) Case 2 had a left lung upper lobe cryptococcoma; iii) Cases 3, 4 and 5 had 
disseminated cryptococcosis, involving the breast tissue, lung, cerebrum and isolated from 
blood.  
(See appendix 2, online supplement, for comprehensive case vignettes with expanded image 
series.) 
Baseline basic laboratory tests 
Laboratory tests were done, on average, 2 years (for 3 patients) and 10 years (for 1 patient), 
since the completion of induction intravenous antifungal therapy; 4/5 patients were on 
maintenance oral fungal therapy at the time of the tests.  
All the patients had normal renal and liver functions. Whereas one patient (case 3), had an 
absolute leukopenia of 3000 cells/µl (Reference ranges:  4000-1000 cells/µl), this was noted to 
have recovered in follow-up blood tests. Significantly, one patient (case 4) had persistent 
absolute lymphopenia of 620 cells/µl. (Reference ranges: Total lymphocytes=1000-4200 
cells/µl). The rest of the basic baseline laboratory tests were unremarkable. (NB: All reference 
ranges as per South Africa National Health laboratory System). 
(See appendix 3, online supplement, for comprehensive basic laboratory results) 
Important Baseline Immunological Tests. 
All the 5 patients had normal levels of total serum immunoglobulins (IgG, IgA and IgM), B-
cells, NK cells, total complement levels and T-cell subsets (CD3 and CD8). One patient (case 
4) had a low CD4 count of 218 cells/µl and inverted CD4 to CD8 ratio; CD4 lymphopenia 
(<300 cells/µl) persisted during two years of follow-up.  
Whereas one patient (case 3) had normal expression of CD27 and CCR7 (markers of naïve and 
memory T cells, respectively), three other patients (case 1, 2 and 5)) had low levels; while one 
patient (case 4) had no expression of CCR7 at all. Nonetheless, all patients had normal 
stimulated and unstimulated CD4+ cytokine expression for IFN-γ, TNF-α, IL-22 and IL-17. 
When compared to normal transport controls, all patients had normal neutrophil oxidative burst 
results for the PMA and E. coli stimuli. 
All the patients had low levels of recall antibody titers to childhood vaccines given as part of 
SA expanded program of immunisation (EPI): diphtheria (cases 3 and 5), tetanus (cases 1 and 
2), and Hemophilus influenza B (cases 2, 3 and 5). Additionally, all the patients had low serum 
Vitamin D3 levels (median level of 52 nmol/L), with patients 2 and 4 having significant 
deficiency (mean level of 46.15 nmol/L). 
Figure 3 shows flow cytometry plots of the CD4 cell deficiency in case 4.  
(See appendix 4, online supplement, showing summaries of the important baseline 
immunological test results; and further flow cytometry plots for various cytokine assays) 
38 
 
Figure 3: Flow cytometry plots showing CD4 deficiency in case 4. 
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KEY: FLOW CYTOMETRY PLOTS 
In healthy subjects, the ratio of CD4 to CD8 is at least 2:1; meaning that 
there are at least twice as many CD4 cells as there are CD8 cells. This is true 
for the healthy controls and Cases 1, 2, 3 and 5. However, Case 4 has an 
inverted CD4 to CD8 ratio. This is consistent with severe CD4 deficiency 
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Discussion 
This is the first African study to evaluate a cohort of patients with IFD, with stratified basic 
and advanced immunology investigations. The key findings of our study include: i) the 
majority of IFD have an easily identifiable secondary immunodeficiency, most commonly 
advanced HIV/AIDS; ii) detailed immunological work-up can identify known primary 
immunodeficiencies e.g. idiopathic CD4 lymphopenia; iii) possible secondary contributing 
factors e.g. vitamin D3 insufficiency or suboptimal vaccine antibody titres that may contribute 
to increased fungal susceptibility could be detected and treated; and iv) the majority of cases 
had normal immune cell numbers and fungal-stimulated adaptive cytokine production. A whole 
genome sequencing approach is underway to screen for known or unknown monogenic primary 
immune  deficiency.  
In high prevalence settings, advanced HIV/AIDs is the single most common risk factor, and 
Cryptococcus neoformans is the most common organism[6]. In Brazil, for example, Prado et al 
report about 51% of deaths from systemic mycosis in HIV positive patients was due to invasive 
cryptococcosis[7]. In Sub-Saharan Africa, one million cases of disseminated cryptococcosis are 
reported annually, with over 600,000 deaths per year among HIV infected patients(1). In South 
Africa, Jarvis et al showed cryptococcal meningitis accounting for 63% of all cases of 
meningitis in HIV patients, with a mortality of almost 50% despite treatment[8].  
Despite low CD4 count being the main risk of disease, not all HIV patients with low CD4 
counts develop cryptococcal disease, or IFD. In fact, infection rates differ between patients 
with similar levels and durations of CD4 lymphocytopenia[9]; reflecting the complexity of anti-
fungal immunity, and possible compensation of barrier and innate immunity, as well as 
differential depletion of TH1 and TH17 subsets with advancing HIV. Other causes of 
secondary immune deficiency identified among IFD patients in this study included: diabetes, 
autoimmune diseases (e.g. SLE); major organ failure, malignancy (solid organ and 
haematological), and organ transplant. These diagnoses highlight the need for thorough work-
up that should include mandatory HIV testing, fasting blood sugars and HBA1C, ANA, possible 
BMAT, and organ-function tests e.g. renal and liver function.  
Our detailed immune work-up identify partial to severe vitamin D deficiency and poor specific 
vaccine titres in all cases. Vitamin D modulates both innate and adaptive immunity via complex 
transcriptional mechanisms[10]. The development of active TB has been linked to vitamin D 
deficiency and seasonal changes in Vitamin D levels[11,12]. No studies have demonstrated a link 
with increased susceptibility to fungal disease; but there are in vitro studies that demonstrate 
beneficial effects of  Vitamin D3 (active form) on Th1 cytokines production[13,14]. Thus, it is 
reasonable to suggest this may have a small contributory role for the association noted in this 
study. However, we are unable to say whether this association is causal or a consequence of 
infection. Further studies are needed to answer this. Furthermore, vitamin D deficiency is easily 
amenable to treatment. 
Antibody deficiency is not known to increase risk of fungal disease, however measurement of 
recall antibody titres to various childhood vaccines may be a marker for impaired humoral 
immune function. None of our cases had an increased burden of bacterial infections, but 80% 
had low specific antibody titres. Cases will receive vaccine boosters with measurement of 
subsequent humoral responses, confirming an intact endogenous antibody response. In 
addition, we noted that 80% of IFD cases were atopic; higher than the general population 
prevalence. Hyper IgE syndrome is well-described to link severe allergic disease and fungal 
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susceptibility. Although none of the cases had this syndrome, several genetic pathways overlap 
between allergic and fungal diseases[15].   
Several primary immunodeficiencies (PIDs) have been described to underpin (increased) 
susceptibility to IFD. In North Africa, Lanternier et al reported on a series of 17 IFD patients,  
ages 25 to 75 years; all of whom were diagnosed with autosomal recessive CARD 9 deficiency 
with deep dermatophytosis; 15 of these patients shared a common ancestral gene[3]. There are 
no studies from sub-Saharan Africa detailing PIDs underlying IFD or endemic mycosis such 
as Emmonsia spp.   We identified one patient with idiopathic CD4 lymphocytopenia – a known 
PID associated with disseminated cryptococcal disease[4]. Several gene mutations including 
hypomorphic RAG1, Heterozygous UNC119 and MAGT1 mutations have been found as the 
cause for a CD4 lymphopenia immune phenotype[16-18]. We are pursuing a genetic diagnosis 
for this case. An interesting additional contributing factor in this case is the role of substance 
abuse.  Animal studies have demonstrated that recreational drugs can alter T-cell function[19]. 
However, Chao et al conducted a longitudinal study whose results indicated that use of these 
substances does not adversely affect the numbers and percentages of circulating CD4 or CD8 
T cells in either HIV-uninfected or -infected patients[20]. Functional immune abnormalities, 
either of phagocyte or T-cell function (proliferation and cytokine responses), have been 
identified in patients with known PIDs associated with IFD, including CARD9, STAT1, 
STAT3, CD40L, IL12R1 and IFNRD[21-23]. Thus, the normal functional immune responses 
in our cases suggest that none of these patients have another a known monogenic PID. 
This study is a case series of only five patients and thus has limitations. However, we have 
included all patients at a single centre with IFD over a ten-year period, thus providing 
practicing clinicians with a sense of the relative contributions of secondary immunodeficiency 
and appropriate investigations. The study relied on downstream contact of patients from a 
database, thus eight potential patients with an underlying immune defect were not included (4 
dead, and 4 untraceable); these patients may have increased the detection of PID.  
 Which patients should be referred for Immunological work-up? 
Patients who have individual or family history of severe, persistent, unusual, and recurrent 
infections (SPUR algorithm) should be referred for a full immunological work-up[24,25]. All 
patients with IFD should be investigated. This should include: i) a detailed family and clinical 
history; ii) exclusion of secondary immunodeficiencies e.g. HIV, DM, autoimmunity and 
malignancy, iii) step-wise immune work-up starting with immune cell numbers – the full blood 
count differential identified the case of idiopathic CD4 lymphopenia; proliferative T-cell and 
phagocyte function. Investigations for other possible contributing factors such as allergy and 
vitamin D status, allows optimisation of factors easily amendable to treatment. Patients should 
be referred to sub-specialist immunology or infectious disease centres for more specialised 
cytokine and genetic studies if warranted.  
Conclusion 
We have described the clinical and immunological characteristics of five South African 
patients with invasive fungal diseases, and no secondary immunodeficiency. We have 
identified one known PID phenotype and possible contributing factors amenable to 
intervention through detailed work-up. Further planned genetic study may identify novel gene 
defects associated with increased susceptibility to fungal disease in African populations. We 
also recommend further studies to look into possible relationship between vitamin D deficiency 
and IFD. 
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ONLINE SUPPLEMENTS 
Appendix 1: Infectious work-up at presentation with IFD 
     Table 1: infectious disease work-up during diagnosis of IFD  
Case 1 2 3 4 5 
INFX HIV Neg Neg Neg Neg Neg 
RPR Positive Neg Neg Neg Neg 
HBsAg Neg Neg Neg Neg Neg 
HCV Ab Neg Neg Neg Neg Neg 
Blood culture Neg Neg +MSSA Neg Neg 
CSF Polys 0-2 0 0 1 0 0 
Lymphs 0-2 4 1 16 0 0 
Erythro 0 0 125 1 1760 0 
Glucose 60% of 
serum 
glucose 
4.1 4.8 3.3 3.5 4.1 
Proteins <0.45g/dL 0.28 0.28 0.22 0.39 0.28 
CLAT Neg Neg Neg Neg Pos Neg 
Bacteria None None None None None None 
Culture Neg Neg Neg Neg Neg Neg 
Malign Neg Neg Neg Neg Neg Neg 
URINE Leuco 1+  3+ 2+  
 Nitrites Nil  Nil Nil  
 Fungi Nil  Nil Nil  
 Culture Neg  Neg Neg  
SPUTUM Bacteria Pos Neg  Neg Pos 
 Fungi - -  Yeasts Nil 
 AFBs Nil Nil  Nil Nil 
 GXP Neg Neg  Neg Neg 
 Culture N. flora Mix gr  Neg S.pneum 
 TB Culture Neg Neg  Neg Neg 
FLUID Bacteria  Nil  Neg  
 Culture  Neg  Neg  
 Z-N stain for AFBs  Neg  Neg  
 TB culture  Neg  Neg  
 Cytology  Neg  +Fungi  
TISSUE Bacteria Nil Nil Nil Nil Nil 
 Fungi Neg Neg Pos Neg Neg 
 Culture Pos Neg Pos Neg Neg 
 Z-N stain for AFBs Neg Pos Neg Neg Neg 
 TB culture Neg Neg Neg Neg Neg 
 Malignancy Neg Neg Neg Neg Neg 
 Histology +Fungi +Fungi +Fungi +Fungi +Fungi 
(Infx=infection screen, CSF=cerebrospinal fluid, RPR=rapid plasma regain test for syphilis, 
MSSA=methicillin sensitive Staphylococcus aureus, CLAT=cryptococcal latex agglutination 
test, Z-N=Ziehl-Neelsen test, GXP=gene expert test, TB=tuberculosis, AFBs=acid fast 
bacilli) 
 
45 
 
Appendix 2a:  Case Summaries 
 
Table 2: Patient characteristics   
Case 1 2 3 4 5 
Age at Dx 
(Yr) 
49  68 36 41 44 
Sex Male Male Female Male Male 
Self-reported 
ethnicity; 
birth place  
Black,  Mixed Black Mixed Mixed 
Birth 
province 
E. Cape W. Cape E. Cape W. Cape W. Cape 
Parents 
related 
No No No No No 
Family 
history of 
fungal 
infection 
Nil Nil Son with 
Tinea corporis 
Brother with 
Tinea corporis 
Nil 
Comorbidity Nil Hypertension Nil Substance 
abuse 
Nil 
EPI 
Vaccination 
(BCG scar) 
Yes Yes Yes Yes Yes 
IFD diagnosis Cerebral 
aspergillosis 
Disseminated 
cryptococcosis 
Disseminated 
cryptococcosis 
Disseminated 
cryptococcosis 
Disseminated 
cryptococcosis 
Sites/organs 
involved 
Brain Lungs Breast, Blood Breast, CSF, 
Blood 
Lungs, Blood 
Fungus Aspergillus 
fumigatus 
Cryptococcus 
neoformans 
Cryptococcus 
neoformans 
Cryptococcus 
neoformans 
Cryptococcus 
neoformans 
CLAT - Negative Positive Positive Positive 
 
(Dx=diagnosis; EPI=Expanded program of immunization; BCG=Bacillus Calmette-Guerin; 
CLAT=cryptococcus latex agglutination test) 
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Table 3: Case 1 summary 
Case 1 
Demographics 
  
Date of birth 19/12/1965 
Sex Male 
Self-identified Ethnicity Black African 
Birth place Eastern Cape 
Are your parents related? No 
  
Medical History 
  
BCG scar present Yes 
Significant childhood &medical history Nil 
Significant Family medical history Father=Pulmonary TB& Ca prostate; Mom 
died of meningitis; 1 son has been treated 
for pulmonary TB 
Significant social history Nil 
Year of first diagnosis of IFD 2014 
Presenting complaints 4months of Recurrent headaches with 3rd, 
4th and 6th cranial nerve palsy 
Date of first admission 1/10/2014 
Date of discharge 1/11/2014 
Number of admissions 4 
  
Invasive Fungal Disease Diagnosis 
  
Genus Aspergillus 
Species Fumigatus 
Samples and sites for diagnosis Brain abscess 
Direct microscopy Branching fungal hyphae 
Fungal culture Aspergillus fumigatus 
Histopathology Free lying aggregates of fungal hyphae 
showing septations and acute angle 
branching, consistent with Aspergillus spp. 
Final clinical diagnosis Cerebral aspergillosis 
Management and follow-up 
  
First-line treatment IV Voriconazole 
Duration of first line therapy 2 weeks 
Adjunctive treatment Drainage of brain abscess; Steroids given 
(IV Dexamethasone followed by oral 
prednisone) 
  
Secondary prophylaxis Oral Voriconazole 
Duration of secondary prophylaxis Ongoing 
Associated infections/conditions Neurosyphilis, treated with IV penicillin 
Follow-up Ongoing at the ID clinic 
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Table 4: Case 2 summary 
Case 2 
Demographics  
  
Date of birth 23/10/1946 
Sex Male 
Self-identified Ethnicity Coloured African 
Birth place Cape Town 
Are your parents related? No 
  
Medical History  
  
BCG scar present Yes 
Significant childhood &medical history Recurrent tinea corporis; shingles in 
puberty; diagnosed with HPTN and DM in 
Jan 2017 
Significant Family medical history 1 grandchild has asthma, another grandchild 
has eczema 
Significant social history Nil 
Year of first diagnosis of IFD 2014 
Presenting complaints 3 months of dysphagia, hoarse voice and 
weight loss 
Date of first admission 16/03/2015 
Date of discharge 28/03/2015 
Number of admissions 2 
  
Invasive Fungal Disease Diagnosis  
  
Genus Cryptococcus 
Species Neoformans 
Samples and sites for diagnosis Left upper lobe lung tissue 
Direct microscopy Budding yeast cells 
Fungal culture Cryptococcus neoformans 
Histopathology Scattered granulomas with big reactive 
follicular hyperplasia and some histiocytes. 
Budding yeast cells noted; consistent with a 
cryptococcoma 
Final clinical diagnosis Pulmonary cryptococcosis 
Management and follow-up  
  
First-line treatment No antifungals given 
Duration of first line therapy No antifungals given 
Adjunctive treatment Excision of the left upper lobe of lung 
(partial pneumonectomy) 
  
Secondary prophylaxis No antifungals given 
Duration of secondary prophylaxis No antifungals given 
Associated infections/conditions Pulmonary tuberculosis; treated for 6 
months 
Follow-up Discharged from ID clinic after 1 more visit 
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Table 5: Case 3 summary 
Case 3 
Demographics  
  
Date of birth 19/04/1978 
Sex Female 
Self-identified Ethnicity Black African 
Birth place Cape Town 
Are your parents related? No 
  
Medical History  
  
BCG scar present Yes 
Significant childhood &medical history Eczema 
Significant Family medical history Mother has Eczema and allergic rhinitis; 
4yr-old son has recurrent skin rashes and 
rhinitis (HIV negative) 
Significant social history Nil 
Year of first diagnosis of IFD 2015 
Presenting complaints 3 weeks history of left breast swelling; 
found to be breast abscess 
Date of first admission 15/08/2015 
Date of discharge 14/09/2015 
Number of admissions 3 
  
Invasive Fungal Disease Diagnosis  
  
Genus Cryptococcus 
Species Neoformans 
Samples and sites for diagnosis Serum CLAT=positive; Breast tissue 
Direct microscopy Numerous budding yeast cells 
Fungal culture Cryptococcus neoformans 
Histopathology Deep fungal infection with budding yeast 
cells 
Final clinical diagnosis Disseminated cryptococcosis with breast 
involvement 
Management and follow-up  
  
First-line treatment IV Amphotericin B 
Duration of first line therapy 8 weeks 
Adjunctive treatment Incision and drainage of breast abscess; 
debridement of necrotic breast tissue 
  
Secondary prophylaxis Oral Fluconazole 
Duration of secondary prophylaxis Ongoing 
Associated infections/conditions MSSA septic shock due to J-line infection 
Follow-up Ongoing at the ID clinic 
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Table 6: Case 4 summary 
Case 4 
Demographics  
  
Date of birth 18/10/1975 
Sex Male 
Self-identified Ethnicity Coloured African 
Birth place Cape Town 
Are your parents related? No 
Medical History  
  
BCG scar present Yes 
Significant childhood &medical history Recurrent tinea corporis in childhood 
Significant Family medical history Dad had pulmonary TB, 1 brother had 
recurrent tinea corporis and onychomycosis, 
1 daughter has eczema and asthma 
Significant social history Longstanding smoking of 
methamphetamines, mandrax and tobacco 
Year of first diagnosis of IFD 2016 
Presenting complaints 3 months of right breast swelling with 
associated recurrent headaches 
Date of first admission 24/07/2016 
Date of discharge 4/08/2016 
Number of admissions 1 
Invasive Fungal Disease Diagnosis  
  
Genus Cryptococcus  
Species Neoformans 
Samples and sites for diagnosis Serum CLAT=positive, CSF 
CLAT=positive; breast aspirate and breast 
tissue 
Direct microscopy Numerous budding yeast cells 
Fungal culture Cryptococcus neoformans 
Histopathology Scattered budding yeast cells seen with 
surrounding necrotizing inflammation; 
morphologically Cryptococcus spp. 
Final clinical diagnosis Disseminated cryptococcosis with cerebral 
and breast involvement 
Management and follow-up  
  
First-line treatment IV Amphotericin B 
Duration of first line therapy 7 days. Patient left hospital AMA. Intended 
to be 6 weeks of IV Amphotericin B 
Adjunctive treatment Aspiration of breast abscess; followed by 
excision of breast mass. 
Secondary prophylaxis Fluconazole 
Duration of secondary prophylaxis Ongoing 
Associated infections/conditions Genital warts-cauterization done 
successfully 
Follow-up Ongoing follow up at the ID clinic 
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Table 7: Case 5 summary 
Case 5 
Demographics  
  
Date of birth 10/11/1963 
Sex Male 
Self-identified Ethnicity Coloured African 
Birth place Cape Town 
Are your parents related? No 
  
Medical History  
BCG scar present Yes 
Significant childhood &medical history Spontaneous pneumothorax in 2002; 
Steroid-induced AVN of Left femur head, 
with THR in 2014 
Significant Family medical history 1 sister died at age 2-3 years, of unknown 
cause, 1 daughter has Penicillin allergies  
Significant social history Chronic cigarette smoking 
Year of first diagnosis of IFD 2007 
Presenting complaints 2 weeks of cough with hemoptysis; with 
mass found on the Rt lung hilar region; 
subsequently had focal seizures, with 
cerebral mass noted 
Date of first admission 12/12/2007 
Date of discharge 22/02/2008 
Number of admissions 3 
  
Invasive Fungal Disease Diagnosis  
Genus Cryptococcus 
Species Neoformans 
Samples and sites for diagnosis Serum CLAT=positive, CSF 
CLAT=positive, Lung tissue 
Direct microscopy Numerous budding yeast cells 
Fungal culture Cryptococcus neoformans 
Histopathology Numerous medium to large encapsulated 
yeasts of Cryptococcus spp., with associated 
granulomatous inflammation 
Final clinical diagnosis Disseminated cryptococcosis with 
pulmonary and cerebral involvement 
Management and follow-up  
  
First-line treatment IV Amphotericin B 
Duration of first line therapy 6 weeks 
Adjunctive treatment Excision of lung mass (partial 
pneumonectomy); anticonvulsant therapy 
  
Secondary prophylaxis Oral Fluconazole 
Duration of secondary prophylaxis Ongoing 
Associated infections/conditions Focal seizures; treated for pneumonia 
Follow-up Ongoing follow-up at the ID clinic 
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Appendix 2b: Image series for case vignettes 
   
                Figure 1                                            Figure 2                                                 Figure 3 
Case 1: Figure 1 MRI brain showing enhancing left cavernous sinus mass, Figure 2 MRI 
showing interval deterioration with a large left temporal lobe abscess communicating with 
the left para-cavernous sinus, and Figure 3 CT scan showing near complete resolution to 
normal left cavernous sinus morphology with mild residual expansion only. 
   
                Figure 1                                         Figure 2                                          Figure 3 
Case 2: Figure 1 CXR and Figure 2 CT chest, both showing spiculated left upper lobe mass. 
Figure 3 is a post-op CXR following excision of the mass.                                                  
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            Figure 1                                                 Figure 2                                                  Figure 
3 
Case 5: Figure 1 CXR done in 2012 following right partial pneumonectomy, Figure 2 CT 
brain in 2012 showing cerebral parenchymal lesions with peripheral enhancement, and 
figure 3 CT brain in 2018 showing essentially unchanged cerebral parenchymal lesions with 
peripheral enhancement, and calcification noted. 
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Appendix 3: Basic laboratory tests at diagnosis of IFD 
Table 8: Basic laboratory tests done during diagnosis of IFD 
Case 1 2 3 4 5 
FBC WCC(*X109/L) 4.0-10 6.61 8.5 3.00 7.10 9.46 
HB(g/dL) 13.5-
18 
17.4 9.6 10.4 14.3 15.8 
MCV(fL) 79-96 80.3 80.1 82.8 85.7 90.2 
PLTS(*X109/L) 138-
454 
285 489 279 253 234 
DIFF Neutro(*X109/L) 2.0-
7.6 
3.76 5.73 1.4 6.8 4.31 
Lymph(*X109/L) 1.0-
4.2 
2.27 1.96 0.9 0.62 4.19 
Mono(*X109/L) 0.1-
0.8 
0.50 0.59 0.28 0.70 0.60 
Eosino(*X109/L) 0-0.44 0.02 0.17 0.00 0.16 0.27 
Basophil(*X109/L) 0-0.10 0.02 0.06 0.00 0.04 0.06 
INFLAMM ESR (mm/hr) 0-15 40 - - - 15 
CRP(mg/L) 0-5 9 - - - 37 
RENAL Na+(mmol/L) 135-
145 
136 140 137 141 139 
K+(mmol/L) 3.5-
5.1 
4.9 5.2 4.4 4.3 4.7 
Urea(mmol/L) 2.6-
7.0 
4.9 5.2 4.9 4.5 4.4 
Creat(µmol/L) 60-
104 
95 96 66 89 79 
eGFR(ml/min/1.73m2) >60 >60 >60 >60 >60 >60 
LIVER Bili total(µmol/L) 0-21 12 7 3 9 5 
Bili conj(µmol/L) 0-6 4 3 <1 3 2 
Tot Prot(g/L) 60-83 73 88 64 80  
Albumin(g/L) 35-54 53 46 41 49 49 
ALP(U/L) 42-
124 
91 103 98 92 69 
GGT(U/L) 0-62 77 24 94 40 37 
ALT(U/L) 5-39 26 16 26 28 6 
AST(U/L) 5-39 23 28 25 24 22 
THYROID TSH(mIU/L) 0.26-
4.3 
2.3 3.1 0.36 1.21 2.27 
GLUCOSE Fasting(mmol/L) 4-6.9 5.3 6.4 5.8 6.8 6.2 
HBA1C% <5.7  5.4  4.8  
AUTOIMM ANA titer Neg Neg Neg Neg Neg 
(FBC=full blood count, Diff=differential count, Inflamm=inflammatory markers, 
Autoimm=autoimmune disease screen, WCC=total white cell count, HB=hemoglobin, 
MCV=mean corpuscular volume, PLTS=platelets, Neutro=neutrophils, Lymph=lymphocytes, 
Mono=monocytes, Eosino=eosinophils, ESR=erythrocyte sedimentation rate, CRP=C-
reactive protein, Na+=serum sodium, K+=serum potassium, Creat=creatinine, 
eGFR=estimated glomerular filtration rate, ANA=antinuclear antibody) 
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Appendix 4a: Baseline Laboratory and Immunology Results 
Table 9: Basic immunology results 
Case 1 2 3 4 5 
WCC (*x109/L) 4.0-10 6.61 8.5 3.00 7.10 9.46 
Differential 
Count 
(*x109/L) 
Neutro 2.0-7.6 3.76 5.73 1.4 6.8 4.31 
Lymph 1.0-4.2 2.27 1.96 0.9 0.62 4.19 
Hemoglobin (12-18 g/dl) 17.4 9.6 10.4 14.3 15.8 
Platelets (138-454 X109) 285 489 279 253 234 
Total IgG (7.0-16 g/L) 16.43 16.9 16.44 16.24 12.91 
Total IgA (0.7-4.0 g/L) 3.25 3.77 3.77 1.78 2.53 
Total IgM (0.4-2.3 g/L) 1.67 1.67 0.64 1.27 0.81 
CD3 cells (527-2846 cells/µl) 1253 1134 668 1325 2429 
CD4 cells (332-1642 cells/µl) 795 726 400 218 1606 
CD8 cells (170-811 cellsµ/l) 458 418 232 1034 886 
B cells (78-899 cells/µl) 265 256 119 281 1021 
NK cells (67-1134 cells/µl)  892 257 217 367 877 
Total complement levels 810 790 690 717 852 
Serum CLAT - Negative Positive Positive Positive 
 
(NK=Natural killer cells; CLAT=cryptococcal latex agglutination test) 
 
Figure 1: Line chart representation of the total leucocyte count, as well as absolute 
neutrophil and lymphocyte counts. Units is cells/L. 
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Figure 2: Bar graph representation of Lymphocyte subsets, natural killer (NK) cells, 
and Total complement levels. Units is cells/µl. 
 
 
 
 
Appendix 4b: Recall titers to vaccines, Neutrophil function and Vitamin D levels 
Table 10: Antibody recall titers, neutrophil function, and Vitamin D levels 
Case 1 2 3 4 5 
Current antibody levels      
C. diphtheriae IgG 0.19 0.10 0.06 0.46 0.06 
C. tetani IgG 0.02 0.01 0.31 1.50 0.56 
H. influenza B IgG 19.93 0.23 0.68 0.09 >9.00 
S. pneumonia IgG 47.3 283 50.70 75.20 123.75 
Oxidative burst for Neutrophils 
Wash 0-10% 3.7 3.9 16.9 2.4 
fMLP 1-20% 8.5 14.1 45.6 9.7 
PMA 99-100% 99.6 100 100 100 
E. coli 95-100% 99.6 100 99.9 100 
Serum Vitamin D Level in nmol/L (<50 =Deficient, 50-72.5=Insufficient, 
>72.5=Sufficient) 
 52 47.2 53.1 45.1 60.2 
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Table 11: Reference ranges of the vaccine recall titers 
 
 
 
 
 
 
 
 
 
 
 
Addendum to “Current antibody levels”. This is a measure of the current antibody recall 
titers to various vaccines; based on National Health Laboratory Services guidelines. 
Corynebacterium diphtheriae IgG (IU/mL) 
            Protective Ranges: 
                    <0.01 IU/mL   No protection. 
              0.01 - 0.09 IU/mL   Minimal protection. 
              0.10 - 0.99 IU/mL   Safe protection. Booster recommended. 
              1.00 - 1.49 IU/mL   Booster after 5 years. 
              1.50 - 1.99 IU/mL   Booster after 7 years. 
                    >2.00 IU/mL   Booster after 10 years. 
 
 Clostridium tetani IgG          (IU/mL) 
            Protective Ranges: 
                    <0.01 IU/mL   No protection. 
              0.01 - 0.10 IU/mL   No safe protection. Booster recommended. 
              0.11 - 0.50 IU/mL   Sufficient protection. Booster improves protection. 
              0.51 - 1.00 IU/mL   Sufficient protection. Booster not necessary. 
              1.01 - 5.00 IU/mL   Long term protection. Booster after 5-10 years. 
                    >5.00 IU/mL   Long term protection. Booster after 10 years. 
 
 
Haemophilus influenza B IgG      (mg/L) 
            Protective Ranges: 
                   At 0-1 years   >0.84 mg/L 
                   At 1-2 years   >1.00 mg/L 
                    At >2 years   >1.50 mg/L 
 
Streptococcus pneumoniae IgG      (mg/L) 
            Protective Ranges: 
                  At 0-1 years   > 9.20 mg/L 
                  At 1-2 years   > 4.60 mg/L 
                  At 2-3 years   >12.30 mg/L 
                  At 3-4 years   >14.60 mg/L 
                   At >4 years   >35.00 mg/L 
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Appendix 4c: Flow cytometry plots 
Figure 3: Flow cytometry series 
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CD4+ CCR7/CD27 on CD45RA-/+ 
CD45 RA-(1st Panel) and CD45 RA+(2nd Panel): Patients 
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Note that Case 4 had absent CD27 and CCR7 expression; therefore, showing absence of 
naïve and memory T cell populations.  
 
CD4+ cytokine expression: IFN-g & TNF-a CD4+ cytokine expre sion: IL-22 & IL-17 
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Compared to healthy controls, all patients had normal stimulated and unstimulated CD4+ 
cytokine expression for IFN-γ and TNF-α. 
 
CD4+ cytokine expression: IL-22 & IL-17 
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LIST OF ABBREVIATIONS 
ABBREVIATION  
HIV Human immune-deficiency virus 
AIDS Acquired immune deficiency syndrome 
CD e.g. CD4 Cluster of differentiation 
IL e.g. IL17 Interleukin 
TH/Th T-helper cells 
CARD9 Caspase recruitment domain-containing protein 9 
CNS Central nervous system 
IFN Interferon 
GM-CSF Granulocyte-monocyte colony stimulating factor 
TNF Tumor necrosis factor 
PID Primary immune deficiency 
FBC Full blood count 
CRP C-reactive protein 
ESR Erythrocyte sedimentation rate 
CT scan Computerized tomography scan 
MRI Magnetic resonance imaging 
NHLS National health laboratory services 
CCR C-chemokine receptor 
HREC Human research and ethics committee 
UCT University of Cape Town 
CRF Case report form 
APACHE Acute physiology and chronic health evaluation 
CHC Community health clinic 
MMed Master of medicine degree 
GIT system Gastro-intestinal system 
HIb Hemophilus influenze type B 
PHA mitogen Phytohemagglutinin 
PMA mitogen Phorbol myristate acetate 
VZV Varicella zoster virus 
 
FIGURES, TABLES AND APPENDIX 
Figure 1: - Innate and adaptive responses to fungal infections 
Table 1: - Causes of secondary immunodeficiency leading to increased susceptibility to 
invasive fungal infections 
Table 2: - Primary immunodeficiencies associated with invasive fungal diseases 
Appendix 1: - Informed consent 
Appendix 2: - Case report form 
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ABSTRACT 
Whereas fungi are ubiquitous, only a small number cause infections in humans. Innate and 
adaptive immune responses are usually effective in preventing disease or restricting to non-
invasive infections. Invasive and severe fungal disease is usually restricted to an 
immunocompromised host. Secondary immunodeficiencies, especially HIV/AIDS; account for 
the majority of patients presenting with invasive and/or severe fungal disease, but there is a 
small group of patients with no evidence of a secondary cause; yet with an increased 
susceptibility to disease. A working hypothesis is that these patients may either possess an 
already described yet undiagnosed primary immunodeficiency; or carry novel genetic 
mutations resulting in an increased susceptibility to disease.  
No African studies have conducted detailed immunological or genetic analysis of HIV-
negative patients presenting with invasive fungal disease This study will be a cross-sectional 
study to describe the clinical and immunological characteristics of a series of such patients, 
seen at Groote Schuur Hospital in Cape Town; South Africa. Future studies will then 
examine the genetics of susceptibility in this cohort, looking for novel mutations. Future 
studies will then examine the genetics of susceptibility in this cohort, looking for novel 
mutations.  
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INTRODUCTION 
Fungi are a heterogeneous group of eukaryotes consisting of different morphological forms, 
and mainly identified by their lack of chlorophyll and presence of a rigid cell wall [1]. The 
main forms include yeasts and yeast-like fungi (reproduce by budding) e.g. Candida and 
Cryptococcus; moulds (grow by branching and extension of hyphae) e.g. Aspergillus, and 
dimorphic fungi (which behave as yeasts in the host but as moulds in vitro) e.g. Histoplasma 
[1, 2]. While thousands of species exist, only around 300 species cause disease in humans. The 
forms of infections include superficial infections of the skin e.g. ring worms, mucocutaneous 
infections e.g. vulvovaginal candidiasis, oral thrush, and local non-invasive infections e.g. 
Aspergillomas (found in old tuberculosis cavities). Invasive fungal infections occur when fungi 
penetrate deep tissues and/or systemic circulation from where they can be disseminated to 
various body systems. They are usually seen in immunocompromised patients, where they 
contribute a significant burden of opportunistic infections, and are often associated with high 
morbidities and mortalities [2, 3]. 
Given the ubiquitous nature of fungi, the immune responses to fungal infections involve both 
innate and adaptive mechanisms (see Figure 1) [4]. The first-line innate mechanism is the 
presence of physical barriers in the form of skin and mucous membranes, which is 
complemented by cell membranes, cellular receptors and humoral factors [4, 5]. Cells of the 
innate system e.g. Natural killer cells, neutrophils, dendritic cells and macrophages, bind 
components of fungal cell walls using pattern recognition receptors and initiate killing by 
means of phagocytosis. C-type lectins such as Dectin-1 and Toll-like receptor 2 are particularly 
important for anti-fungal immunity. These cells also process and present fungal antigens to 
CD4+ T cells, which differentiate toward the protective Th1 and Th17 pathways [6]. Key 
cytokines necessary include IFN-, IL-17, and IL-12. TH1 and TH2 cells are the most 
important components of the adaptive anti-fungal immune response [6, 7]. Antibodies that kill 
fungal elements via antibody-mediated cytotoxicity and activation of complement are 
adjunctive [8]. In majority of instances, fungal immunity is effective. Invasive fungal infections 
are thus restricted to patients with primary or secondary immunodeficiency. 
Table 1 lists known secondary immunodeficiency states that increase susceptibility to invasive 
fungal diseases. In Africa, the commonest risk factor for invasive fungal disease is advanced 
HIV. In fact, mucosal candidiasis and cryptococcal CNS infections are AIDS-defining illnesses 
[9]. Hematological malignancies, e.g. leukemia and lymphomas; plus their immunosuppressive 
chemotherapies, are other immunodeficiencies predisposing to invasive fungal infections [10, 
11].  
In our infectious disease clinics and medical wards, we have found a small group of patients 
with invasive fungal infections but no known secondary immune deficiency. This project is 
focused on the clinical and laboratory characterization of these patients.  Do these patients have 
an undiagnosed secondary immune deficiency, an already described primary 
immunodeficiency, or do they carry novel genetic mutations with an increased susceptibility 
to invasive fungal disease? In studies of similar patients in other countries, genetic disorders of 
immune functions have been found. Table 2 lists the known genetic defects that have been 
associated with invasive fungal infections. For instance, homozygous mutations in CARD9 is 
associated with deep dermatophytosis of CNS and GIT [12, 13, 14]. Other described 
susceptibilities include isolated CD4 lymphopenia, severe congenital neutropenia, leucocyte 
adhesion deficiency, and in-born errors of the phagocytic respiratory burst activity, necessary 
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for fungal killing. Endemic mycoses have also been linked to congenital errors of IFN-/IL-12 
signaling pathway and acquired auto-antibodies to both IFN- and GM-CSF [15]. 
To our knowledge, there are no African studies that have conducted clinical and immunological 
assessments with or without genetic investigation in HIV-negative cohorts of invasive fungal 
disease without an obvious underlying secondary immunodeficiency. Characterizing these 
patients would be useful not only to diagnose and care for individual patients, but also to 
potentially identify novel genes involved in anti-fungal immunity unique to African 
populations.  
 
 
PURPOSE OF THE STUDY 
The aim of this project is to establish the clinical and immunological characteristics of HIV-
negative patients with invasive fungal diseases, treated at the Groote Schuur Hospital; Cape 
Town, South Africa. 
Hypothesis 
We hypothesize that HIV-negative patients with invasive fungal diseases will not be found to 
have any discernible abnormalities in their baseline immunological work-up; yet may be found 
to have as yet uncharacterized genetic abnormalities affecting immune defense against fungal 
disease.    
 
 
OBJECTIVES 
1. To determine the clinical and baseline immunology characteristics of HIV-negative 
patients treated for invasive fungal disease at Groote Schuur Hospital. 
2. Perform cytokine stimulation assays to examine functional pathways involved in 
susceptibility to fungal infections, including but not limited to TNF-, IFN-, IL1, IL-
6, IL17A, and IL-22. 
3. Conduct whole exome or genome sequencing of patients treated for invasive fungal 
disease, but with no secondary immunodeficiency and normal baseline immunological 
investigation. 
Please note that the scope of this MMed project is restricted to objective 1. The details of 
investigations to be undertaken in Objective 2 and 3 are dependent on the results of objective 
1 and will be performed in collaborations with international collaborators.  
In addition, we also hope that the data generated from this study will provide useful information 
to develop a reasonable set of immune diagnostics to identifiable treatable immune problems 
in a developing country setting. 
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METHODS 
Study Design 
This study is a descriptive, cross-sectional, case series. 
Study Site 
The study will be conducted at the Infectious Diseases and Clinical Immunology clinics of 
Groote Schuur Hospital, Cape Town, South Africa. 
Study Population and Sampling 
The study will include all patients who have been treated for invasive fungal infections at 
Groote Schuur Hospital. The following categories of patients will NOT be included in the 
study: 
• Patients who were/are HIV-positive at the time of infection 
• Patients who have a documented secondary cause for immunosuppression other than 
HIV, e.g. cancer, autoimmune diseases, hematological malignancy, and organ 
transplant  
• Patients who are below 18 years of age. 
• Patients who are unable/refuse to give consent 
The reason for excluding these patients is that the study is based on the hypothesis that the 
subjects to be studied may have an underlying PID. Therefore, we will exclude patients with 
known secondary cause(s) of fungal immune deficiency.  
The patients involved in the study will have in-patient medical records from doctors, nurses, 
and any other allied health workers who managed them, reviewed and relevant data extracted 
(see appendix 2 for case report form). Routine investigations done will be captured from the 
National Health Laboratory Sciences, as well as Radiology and Imaging databases; and the 
relevant data from this will be included in the study. Patients will then be reviewed in the 
Immunology clinic and bloods taken for an in-depth immune work-up (detailed below) to 
exclude known PIDs associated with increased fungal susceptibility. 
MEASUREMENTS 
The data to be collected will include: 
Demographic data for the patients 
• Age 
• Sex 
• Self-reported ethnicity 
• Gender 
Clinical Characteristics 
Family history of fungal infections, detailed genogram 
Admission history of invasive fungal infections 
1. Body system(s) involved 
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➢ CNS                   
➢ Respiratory                
➢ Gastrointestinal             
➢ Other                
2. Diagnostic investigations done during admission 
• Hematological tests e.g. FBC with differential counts 
• Renal Function tests 
• Liver Function tests 
• Markers of inflammation e.g. CRP, ESR 
• Microbiological tests e.g. Blood Cultures, Urine analysis, CSF studies 
• Any baseline immunological testing e.g. Lymphocyte subsets (T-, B- and NK-cell 
numbers)  
• Imaging reports e.g. Chest X-ray, Ct scans, MRI studies 
• Tissue studies e.g. from biopsy, Endoscopy studies 
 
3. Definitive etiological diagnosis i.e. the identity of the fungus (Genus and species), and the 
method used to arrive at the identity 
4. Management given, including the medication used, in what route of administration, what 
duration, and the nature of secondary prophylaxis given 
5. The current status of the subject e.g. the nature of follow up appointment given, and their 
current status of health. 
A case report form will be constructed and validated against international samples. It will then 
be used to collect data from each subject of interest (See Appendix 2)   
IMMUNOLOGICAL WORK-UP 
All patients enrolled will undergo a baseline immunological work-up. They will undergo this 
work-up irrespective of immunological testing done at the time of admission, provided that 
they are culture negative at the time of their study visit. They should be considered as treated 
by the infectious disease team.  
Those tests to be performed/available through the NHLS lab would include: 
1. Immunoglobulin levels and measurement of vaccine responses to tetanus, HIb and 
total pneumococcal 
2. FBC with differential count  
3. Total Haemolytic complement  
4. DHR (dihydrorhodamine) testing for neutrophil respiratory burst function. 
5. Lymphocyte subsets and basic T-cell proliferation in response to mitogens PHA and 
PMA (performed at Tygerberg hospital NHLS) 
6. Vitamin D levels 
  
Those tests to be performed by co-investigators in the Department of Pathology: -  
1. Naïve and memory CD4 and CD8 subsets as well as TH1 and TH17 numbers 
(measured via CXCR3, CCR6+ and CCR4+) 
2. Innate and T cell cytokine production to a range of mitogens and PRRs (e.g. TLR, 
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lectins) and recall antigens, such as candida (and other available fungal antigens) and 
Mycobacterium tuberculosis. 
 
Exploratory assays to be attempted depending on agreement of overseas laboratory to 
perform without cost: - 
1. Autoantibody measurements to IFN-, IL17A and GM CSF 
  
SAMPLE STORAGE AND GENETIC TESTING 
In addition to the baseline testing as outlined above, we will store serum and peripheral blood 
mononuclear cells (PBMCs) for future functional and cytokine work depending on the results 
of objective 1.  We may need to ship some samples to overseas labs of collaborating researchers 
for such, and for more advanced testing, including genetic tests. We will inform the HREC of 
planned further analyses; and patients will be required to consent to sample storage for 15 
years, as well as sample shipment overseas. 
STATISTICAL ANALYSIS 
Coded data will be entered into Red-cap secure data-base for analysis. 
Descriptive statistics will be used to characterize the targeted sample in terms of demographics, 
clinical history and response to management.  Continuous variables will be described using 
means (standard deviations) or medians (inter-quartile ranges), while categorical variables will 
be expressed as frequencies and percentages.  Depending on the nature and distribution of the 
variable, group comparisons will be conducted using either parametric tests (two-sample t-test) 
or non-parametric tests (Mann-Whitney U test) for continuous variables, while Chi-square or 
Fisher’s Exact tests will be used to test for associations between categorical variables.  Data 
will be presented in form of tables, graphs and charts. 
A p<0.05 will be considered statistically significant where appropriate. 
Statistical analysis will be performed using the statistical software, STATA. 
 
TIMELINES 
July  2016-April 
2017 
Complete project design, HREC approvals, collect data from medical 
records 
April-Sept 2017 Data collection from patients 
Sept 2017 Complete data collection 
Sept-Oct 2017 Data processing 
Oct-Dec 2017 Data analysis, Report writing and Preparation for journal articles 
 
 
BENEFITS OF THE STUDY 
The clinical review and testing performed may diagnose previously unidentified disorder in 
individual patients; this may offer individual patient-level benefit. Analysis of the data may be 
useful in setting up a diagnostic algorithm for HIV-negative patients suspected to have an 
underlying susceptibility to invasive fungal diseases. If indicated, the data will be used to 
motivate for further genetic testing. Identification of novel genes and pathways may have future 
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benefit to individual patients, patients with similar clinical phenotypes, may influence 
treatment strategies, and may provide fundamental insights on fungal immunity in humans.   
ETHICAL CONSIDERATIONS  
Permission to conduct this study will be sought from the UCT Human Research Ethics 
Committee (HREC). The study is considered to carry very minimal risk to patients. 
Subject Identification and Confidentiality 
All the information obtained during the study will be handled, stored and confidential. All the 
data collected will be entered in a password-protected UCT-hosted database. All the Study 
documents, materials, and patient Case Report Forms (CRFs) will be regarded as strictly 
confidential and will be stored in a secure place that is only accessible to the study staff. All 
subjects will be de-identified in the study with the use of a study number not linked to any other 
personal identifiers. 
Informed Consent Procedure 
Study participants will be identified from their medical records available in the Infectious 
Diseases Unit of the Groote Schuur Hospital. They will each be introduced by the Supervisors 
to the Lead investigator, who will explain the nature of the study. The lead investigator will 
make sure that each patient understands that participation is voluntary, and that his/her 
subsequent standard of care will not be affected if he/she decides not to participate. The lead 
investigator will then provide the patient with a copy of the informed consent (Appendix 1); 
and answer all the preliminary questions that the patient might have about the study. For any 
illiterate patient, the informed consent will be read to the patient in the presence of a witness 
to ensure that the patient understands the full terms as contained in the informed consent. The 
signature of the said witness shall be captured in the enrolment of such patients. 
Patient’s Risks, Benefits and Re-imbursements 
Patients who are enrolled in this study will benefit from a review of their clinical status by 
participating in a preliminary search for a possible underlying immune dysfunction. The results 
of all testing will be conveyed back to both the patient and treating clinician. There will be 
minimal risk of venepuncture, which includes mild discomfort, and bruising. We will not take 
more than 50mls of blood on one, maximum two occasions (4 weeks apart); the second sample 
will only be collected if we are unable to isolate more than 20 million PBMCs from the first 
sample. Patients will be reimbursed R150 to cover cost of transport and time-off-work. 
BUDGET 
 A sum of R5000 is allocated to all MMed projects. Additional compassionate support for 
testing will be sought from Ampath private immunodiagnostics laboratory as well as the 
Cambridge Immunology Laboratory performing autoantibody testing. Immunological tests 
performed by co-investigators will be covered by their budgets. Additional funding will be 
sought to cover any costs related to further genetic and functional immunology to be performed 
in this patient cohort.  
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Figure 1: - Innate and Adaptive Responses to Fungal infections: -Adapted from Romani 
et al. Nature Review of Immunology; 2004 
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Table 1: - Causes of secondary immunodeficiency leading to increased susceptibility to 
invasive fungal infections 
 
SYSTEM/CATEGORY 
 
EXAMPLES/ASSOCIATED STATES 
 
Vascular 
Central venous catheterization 
 
Autoimmune diseases 
Systemic lupus erythromatosus, rheumatoid arthritis 
Trauma Major surgery (especially abdominal) 
 
 
Immunosuppressants 
Chemotherapy, Steroids, and other immunosuppressant 
medications 
 
Infections 
HIV/AIDS, Tuberculosis (especially post tuberculous fibrosis 
of lungs) 
Severe sepsis/septic shock 
Prolonged use of broad-spectrum antibiotics 
 
Metabolic 
Diabetes, Hypothyroidism 
 
Nutritional 
Severe malnutrition 
Parenteral nutrition 
 
Neoplasms 
Hematological malignancies e.g. leukemia, lymphoma 
Solid organ malignancy 
 
 
Organ failure 
Renal failure 
Hemodialysis 
Liver failure 
Secondary bone marrow failure 
Solid organ transplant 
Hematopoietic stem cell transplant 
 
Critical Illness 
Prolonged ICU stay 
Acute pancreatitis 
Fungal colonization 
APACHE II score >20 
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Table 2: -Primary immunodeficiencies associated with invasive fungal diseases (Adapted 
from Lanternier et al ‘Primary immunodefiencies underlying fungal infections’ Curr Opin 
Pediatr 2013, 25:736–747 
Fungal 
susceptibility 
Disease Associated 
infections 
Immunological 
phenotype 
Gene, transmission 
Deep 
dermatophytosis 
CARD9 
deficiency 
CMC Deficit of IL-17-
producing T cells 
CARD9, autosomal 
recessive 
Aspergillosis STAT3 
deficiency 
Staphylococcus 
aureus 
STAT3 deficiency, 
pithelial lung dysfunction 
STAT3, autosomal 
dominant 
 
Leukocyte 
adhesion 
deficiency, 
type 1 Bacteria 
Impaired neutrophil 
adhesion 
CD18, autosomal 
recessive 
 
Severe 
congenital 
neutropenia 
Bacteria 
invasive 
candidiasis Neutropenia 
ELA2, autosomal 
dominant, HAX1, 
autosomal recessive 
Invasive 
candidiasis 
Severe 
congenital 
neutropenia 
Bacteria, 
invasive 
candidiasis Neutropenia 
ELA2, autosomal 
dominant, HAX1, 
autosomal recessive 
 
Leukocyte 
adhesion 
deficiency 
type 1 Bacteria 
Impaired neutrophil 
adhesion 
CD 18 autosomal 
recessive 
Candida CNS 
infection 
Chronic 
granulomato
us disease 
Bacteria, 
Scedosporium 
NADPH oxidase 
complex defect in 
phagocytes 
CYBB, X-linked or 
autosomal,  
CYBA, NCF1, 
NCF2, NCF4, 
autosomal recessive 
[54,55&,56&,85,86,
89–94] 
 
 
CARD9 
deficiency 
 
Dermatophyte
s, CMC 
Impaired Candida 
killing by PMN 
CARD 9, autosomal 
recessive 
Cryptococcosis 
Autoantibodi
es against 
GM-CSF No 
Neutralizing anti-GM-
CSF autoantibodies 
Unknown 
 
Autoantibodi
es against 
IFN-g Mycobacteria 
Neutralizing anti-IFN-g 
autoantibodies 
 
 
CD40 ligand 
deficiency 
Pneumocystis, 
bacteria 
Hypo IgG, IgA, high 
IgM levels, T/B cell 
cooperation defect 
CD40L, X-linked 
[167,168] 
 
 
MonoMAC 
syndrome 
Environmenta
l 
mycobacteria, 
viruses, fungi 
Monocytopenia, deficit 
of dendritic cells, B and 
NK cell lymphopaenia 
GATA2, autosomal 
dominant [96] 
 
Coccidioidomyco
sis 
Interleukin-
12Rb1 
deficiency 
Mycobacteria, 
Salmonella  
IL12RB1, 
autosomal 
recessive [154] 
 
 
STAT1 GOF 
mutation 
 CMC, viruses  
 
STAT1, autosomal 
dominant 
Histoplasmosis 
IFN-gR1 
deficiency 
Mycobacteria, 
Salmonella  
IFNGR1, autosomal 
dominant 
 
Idiopathic 
CD4 
lymphopenia 
Pneumocystis, 
Cryptococcus, 
CD4 T cells <300 
cells/mm3 
UNC119, autosomal 
dominant [76], 
MAGT1, X-linked 
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[77], RAG1, 
autosomal recessive 
 
DOCK8 
deficiency 
Viruses and 
bacteria T-cell defect 
DOCK8, autosomal 
recessive 
[21,22,25] 
 
 
X-linked 
CD40L 
deficiency 
Pneumocystis, 
bacteria 
Hypo IgG, IgA, high 
IgM levels, T/B cell 
copperation defect 
CD40L, X-linked 
Pneumocystosis SCID 
Bacteria, 
viruses, fungi, 
mycobacteria 
No T cells, with or 
without B and NK 
cell lymphopenia 
>30 genes 
JAK3, autosomal 
recessive 
RAG1, autosomal 
recessive 
RAG2, autosomal 
recessive, 
ARTEMIS, 
autosomal recessive 
ADA autosomal 
recessive 
 
 
X-linked 
CD40 ligand 
deficiency 
Pneumocyst
is, bacteria 
Hypo IgG, IgA, high 
IgM levels, T/B cell 
cooperation defect 
CD40L, X-linked 
[167,168] 
 
MHC class II 
deficiency 
Bacteria, 
viruses, 
fungi T-cell defect 
CIITA, RFXANK, 
RFXC, RFXAP, 
autosomal recessive 
 
NEMO 
deficiency 
Pyogenic 
bacteria, 
mycobacteri
a, viruses T-cell defect 
NEMO, X-linked 
[19] 
 
DOCK8 
deficiency 
 
Viruses, 
bacteria T-cell defect 
DOCK8, autosomal 
recessive 
 
X-linked 
recessive 
Wiskott–
Aldrich 
syndrome 
Bacteria, 
viruses T-cell defect 
WASP, X-linked 
recessive 
 
CARD11 
deficiency  
T-cell defect, 
increased transitional 
B cells, 
hypogammaglobuline
mia 
CARD11, 
autosomal recessive 
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Consent form 
                                                       
FACULTY OF HEALTH SCIENCES 
Department of Medicine 
J-Floor, Old Groote Schuur Hospital, Observatory, 7925 Cape Town; South Africa Phone: +27 
21 4066200; Fax: +27 21 4486815 
Study Title: - Immunological evaluation of HIV-negative invasive fungal disease at Groote 
Schuur Hospital; Cape Town, South Africa.  
                                      “The Fungal Disease Project’’ 
[Prof. Jonathan Peter, (Principal Investigator), Prof. Sipho Dlamini (Co-supervisor), Dr. 
Vonwicks Onyango (MMed Student)] 
Dear Participant, 
Thank you for your interest in this study. This consent form will tell you why we want to do 
this study. You must be 18 years and above to participate in this clinical study. 
Who are the Investigators? 
This study will be carried out by investigators from University of Cape Town. These are 
specialists in immunology and infectious diseases, working at the Groote Schuur Hospital. We 
are working with other investigators in Pretoria, as well as in Netherlands and France, to study 
infections caused by fungi in people; especially those who do not have HIV infection. 
Purpose and Scope of the Research 
Fungi are tiny organisms that are found in the environment (in soil, air, clothes etc.). We easily 
recognize them when they cause our food to go bad, for example, the moulds or yeasts that 
grow on bread, cooked potatoes or vegetables, once these foods have been stored for some 
time. Some of these fungi also cause infections in humans. In most people, fungi do not cause 
severe disease beyond the skin or mucous membranes ( e.g. mouth and genitals), for example, 
ring worms seen on the head and body, or thrush, often seen as whitish sticky material in the 
mouth, or as vaginal discharge, especially among pregnant women. 
Occasionally, some people do suffer from invasive fungal infections. This means that the 
infection goes beyond the skin and mucous membranes, into the blood stream. Once in the 
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blood, the fungal infections can spread to any major organs of the body and cause severe 
disease; e.g. meningitis, pneumonia, or severe diarrhea.  
It is unusual for a person to suffer from invasive fungal infections in the absence of an 
underlying immune system problem. Secondary causes of immune system problems such as 
HIV remain the most common explanation.  
You are being approached to participate in this study because you suffered such a severe 
infection with a fungal organism. You do not have any obvious problem with your immune 
system. 
However, in the absence of these, such as in your situation, it may be explained by another as 
yet unknown problem with your immune system. This may involve your ‘genes’ or genetic 
material. Everyone has ‘genes’, and these are responsible for why people in a family look like 
each other, but different from others. For example, some families have tall members, others 
short, while others may have a particular shape of eyes, nose and feet. These genes are inherited 
from the mother and father; and are passed on to the children from generation to generation.  
In some cases, problems with these genes may be responsible for various types of infections 
and diseases. We want to look closely to try to identify the possible problem with your immune 
system so as to potentially help both you and other similar patients.  
In future, the information and samples that you will provide for this study may also help us to 
better understand how the human immune system fights fungal infections. Other investigators 
elsewhere may also use them to study other diseases. You will not get any direct benefits from 
this study. But we hope that the information we get may benefit others who have similar and 
related diseases. 
Please take as much time as you need to talk about the study with your family, friends, study 
staff and other health care providers as you would like. We are very ready to clarify anything 
that you may not understand; and to answer any questions about anything related to the study.  
 
What will the Study Involve? 
If you agree to participate in this study, we will review your hospital folder with you and ask 
any additional questions pertaining to your history with fungal infections. This interview 
should last approximately 1 hour. We will then ask you for a blood sample of about 50mls 
(about 3-4 table-spoons full). We may also ask you to return four weeks after your first visit 
for a second blood sample, if we are unable to store sufficient blood cells from your first blood 
sample. 
What will happen to the Samples?  
Once we have collected the blood sample from you, we will test some of it in our laboratory 
here at Groote Schuur Hospital, and send some of it to a more advanced laboratory in Pretoria 
for further tests. We may need to send some of the samples, including your genetic material to 
overseas laboratories of our scientific collaborators for even more specialized testing which is 
not available locally. We will store the rest of your samples in our special laboratory here, 
together with other samples given by the other people participating in this study. The samples 
will not be sold. We will store them for a maximum of 15 (fifteen) years for future scientific 
research.  
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What will happen to the data? 
To protect your privacy, we will assign you a study number. This will replace your name in all 
the samples and data related to you. We will do our best to keep this information confidential. 
We will do this by creating a private computer data-base with the study numbers, which will 
be protected by a password, and will only be accessible to the study staff. In order to promote 
greater understanding of your condition, we may need to share your data with our scientific 
collaborators and other investigators across the world in future. When we share this 
information, people will not know your name. Other investigators who want to use your data 
(without your name) will have to first seek permission from our central repository. They will 
commit to using this data for scientific research only.  
Voluntary nature of participation and right to withdrawal from the Study 
It is your personal decision to participate in this study. In other words, it is by your free will 
that you can say ‘Yes’ and join the study; or ‘No’ you don’t want to join. If you participate in 
the study, you can change your mind later and decide that you don’t want to continue 
participating anymore, and that you don’t want your blood sample to be used in the study. 
Please, let us know and we will destroy the sample. If your sample has already been tested and 
data obtained from it at the time that you change your mind, we shall use such information in 
our data analysis. Such data may also have been shared already with other investigators. In that 
case we will not be able to destroy this data. However, should you request it; we can remove 
your data from the central repository. That means no additional researchers can get your data. 
Whether you decide to join this study or not, the way we look after you in this clinic will be 
the same. It is your decision whether to be in this study or not. 
Potential risks associated with the Research  
We must tell you that there are some risks with this study. For instance, things might not go 
very well when taking your blood sample. Most of the time, when we take blood, it is safe. But 
sometimes, when we take blood, some people feel a bit faint, and may have bruising, swelling 
or infection at the site. If this happens, let us know and you will be treated.  
How participants’ privacy will be protected 
We will store your blood samples, together with those of other participants in the study, in a 
locked freezer in our laboratory. Also, whenever we send them for processing, they will be 
under lock and key. The samples, as well as all other information and data obtained from you 
will be assigned your study number in order to protect your personal identity. All this 
information will be stored in a computer data-base which will be protected by a password. It is 
always possible that someone may find out that you participated in this study. However, it is 
very unlikely that this will happen. We will take all measures to ensure that this does not 
happen. 
Potential benefits of participating in the Study 
This study will not help you to immediately get better. However, by conducting additional tests 
in combination with the information obtained from your clinical review, we hope to get a better 
understanding of your condition. This may also help others with the same condition as you, in 
the future. What we are trying to do is difficult and may take a long time. Whether you decide 
to join this study or not will not affect your treatment at our clinic. Your decision to join or not 
is up to you. 
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Participant compensation 
We would like to pay you back for the time and money that you’ll spend to participate in this 
study. We will give you R150 (one hundred and fifty rands) to cover the cost of your time away 
from work and your travel to get to the clinic. 
Return of Results 
When the study is finished, we will share the study research’s general findings with you. We 
will not put these results in your medical records. We will inform you of anything which is 
particularly important to your health. In such a case, we will contact you by phone and put you 
in touch with doctors and other health care workers who can help you. We hope to get 
preliminary results in about twelve months.  
Participant consent 
By signing below, I confirm that the reasons for the study, what will be done, the risks and 
benefits of participating in the study, and what will happen to my samples have been explained 
to me in a language that I understand.   
                                                                                      Your initials here:…………….. 
I confirm that I have been given the opportunity to ask questions about the study by the 
investigator.  
                                                                                     Your initials here:…………….. 
I understand that I may withdraw from the study or refuse future procedures without affecting 
any future medical treatment. 
                                                                                     Your initials here:……………….. 
 
I agree to have my samples stored as outlined in the informed consent document. I give 
permission for my specimens to be stored for future research. 
                                                                                       Your initials here:……………….. 
I agree to have my samples sent to overseas laboratory as outlined in the informed consent 
document. I understand that my specimen will not be used for future research without Ethics 
Committee permission. 
                                                                                       Your initials here:……………….. 
 
I understand that genetic testing will be performed on samples collected from me. I give my 
permission for genetic testing to be performed.  
                                                                                       Your initials here:……………….. 
 
Name of participant……………………………………………….. 
                                                                                      Your initials here:……………….. 
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                                                                  Signature of participant....................................                   
Date.............................................. 
Name of person taking consent/investigator………………………………………………… 
                                                                                      Your initials here:……………….. 
                                                                  Signature of investigator………………………. 
Date............................................... 
 
Name of witness: …………………………………………………. 
                                                                                     Your initials here:……………….. 
                                                                   Signature of witness..................................... 
Date.............................................. 
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Case report form 
Participant details 
Date dd / mm / yyyy Consent Y N 
Study ID  Folder ID  Subject initials  
Contact 
number  
 Home address  
Emergency 
contact  
  
Email 
  
  
Preferred 
method of 
contact 
 
Clinic/CHC  
 
Demographics 
DOB 
dd / mm / yyyy 
  
Gender 
M F  
What is your 
self-identified 
Ethnicity? 
 
Were your parents 
related? 
Y N 
 
Medical history 
Family Hx Y N If yes Chronic Recurrent 
Body 
system 
CNS GIT Resp Other 
Personal Hx 
Age at Dx  Date of initial admission and dx dd / mm / yyyy 
Body 
system 
CNS GIT Resp Other 
 
Length of stay in hospital  
da
ys 
 
wk
s 
Number of 
admissions 
 
Last admission to hospital dd / mm / yyyy Discharge date dd / mm / yyyy 
Body 
system 
CNS GIT Resp Other 
 
Body system Diagnosed condition Clinical diagnosis Current problem 
CNS    
GIT    
Resp    
Other    
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Additional notes  
 
Medical Hx not obtained 
Y N  
Final Dx 
 
Management 
Body system 1 
 
Genus  Species  
Dx confirmed 
 
Microscopy 
 
Culture Histology Other 
Notes 
Anti-fungal 
Treatment 
Fluconazole Route 
Du
r 
Voriconazol
e 
Rout
e 
Dur 
Itraconazole Route 
Du
r 
Posaconazol
e 
Rout
e 
Dur 
Amphoterici
n B 
Route 
Du
r 
Caspofungi
n 
Rout
e 
Dur 
Other Route 
Du
r 
 
2 prophylaxis 
given 
Y N 
 
If yes Drug Route 
Du
r 
 
Body system 2 Genus  Species  
Dx confirmed 
 
Microscopy 
 
Culture Histology Other 
Notes 
Anti-fungal 
Treatment 
Fluconazole 
Route 
Du
r 
Voriconazol
e 
Rout
e 
Dur 
Itraconazole 
Route 
Du
r 
Posaconazol
e 
Rout
e 
Dur 
Amphoterici
n B 
Route 
Du
r 
Caspofungi
n 
Rout
e 
Dur 
Other 
Route 
Du
r 
 
2 prophylaxis 
given 
Y N 
 
If yes Drug Route 
Du
r 
Body system 3 Genus  Species  
Dx confirmed 
 
Microscopy 
 
Culture Histology Other 
Notes 
Anti-fungal 
Treatment 
Fluconazole 
Route 
Du
r 
Voriconazol
e 
Rout
e 
Dur 
Itraconazole 
Route 
Du
r 
Posaconazol
e 
Rout
e 
Dur 
Amphoterici
n B 
Route 
Du
r 
Caspofungi
n 
Rout
e 
Dur 
Other 
Route 
Du
r 
 
2 prophylaxis 
given 
Y N 
 
If yes Drug Route 
Du
r 
83 
 
 
Follow up 
 
Y N   
  
Where GSH MOPD 
GSH 
Immunology 
clinic 
GSH ID clinic 
CHC 
 
_____________ 
DAY 
HOSPITAL 
 
____________ 
 
 
Laboratory results 
 Dates 
Notes 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
FBC WCC      
HB      
MCV      
Platelets      
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
 
Diff count Neutrophils      
Monocytes      
Lymphocytes      
Eosinophils      
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
 
U & E Urea      
Creatinine      
eGFR      
K+      
Na+      
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
 
Liver  Bili total      
Bili conjugated      
Total protein      
Albumin      
ALP      
ALT      
AST      
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
 
Inflammation CRP      
ESR      
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
 
Immunology T cells      
B cells      
NK cells      
Serum lgG      
 Serum IgA      
Serum IgM      
Complement 
levels 
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Microbiology 
 Dates 
Notes 
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
CSF Polys      
Lymph      
RBC      
Protein      
Glucose      
Bacteria      
CLAT      
Culture      
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
 
Blood culture       
      
      
      
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
 
Aspirate  Glucose      
Protein      
LDH      
ADA      
Gram stain      
Bacteria      
Culture      
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
 
Tissue specify      
specify      
specify      
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
 
Xray Head & neck      
Chest      
Abdomen      
Other      
 dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
dd / mm / 
yyyy 
 
Other specify      
specify      
specify      
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 Professor J. Peter 
Allergology & Clinical Immunology 
E-mail: Jonny.Peter@uct.ac.za
Dear Professor Peter 
RESEARCH PROJECT: Immunological Evaluation of HIV-Negative Invasive Fungal Disease at 
Groote Schuur Hospital, Cape Town, South Africa (Masters Candidate Dr V.C. Onyango) 
Your recent letter to the hospital refers. 
You are granted permission to proceed with your research, which is valid until 30 April. 
Please note the following: 
a) Your research may not interfere with normal patient care. 
b) Hospital staff may not be asked to assist with the research. 
c) No additional costs to the hospital should be incurred i.e. Lab, consumables or stationary. 
d) No patient folders may be removed from the premises or be inaccessible. 
e) Please provide the research assistant/field worker with a copy of this letter as verification of approval.
f) Confidentiality must be maintained at all times. 
g) Should you at any time require photographs of your subjects, please obtain the necessary indemnity
forms from our Public Relations Office (E45 OMB or ext. 2187/2188). 
h) Should you require additional research time beyond the stipulated expiry date, please apply for an
extension.
i) Please discuss the study with the HOD before commencing. 
j) Please introduce yourself to the person in charge of an area before commencing. 
k) On completion of your research, please forward any recommendations/findings that can be beneficial to
use to take further action that may inform redevelopment of future policy / review guidelines.
l) Kindly submit a copy of the publication or report to this office on completion of the research.
I would like to wish you every success with the project.
Yours sincerely
DR BERNADETTE EICK 
CHIEF OPERATIONAL OFFICER 
Date: 11 September 2017
C.C. Mr L. Naidoo
Dr H. Aziz          
Professor N. Ntusi 
G46 Management Suite, Old Main Building          Private Bag X, 
Observatory 7925 Observatory, 7935 
Tel: +27 21 404 6288 fax: +27 21 404 6125 www.capegateway.go.v.za 
E-mail : Bernadette.Eick@westerncape.gov.za
GROOTE SCHUUR HOSPITAL 
Enquiries: Dr Bernadette Eick 
signature removed to avoid exposure online
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South Africa Medical Journal: Author Guidelines 
For full instructions, please click on the following URL: 
http://www.samj.org.za/index.php/samj/about/submissions#Authorship 
General article format/layout 
Accepted manuscripts that are not in the correct format specified in these guidelines will be returned to 
the author(s) for correction, which will delay publication. 
General: 
▪ Manuscripts must be written in UK English.
▪ The manuscript must be in Microsoft Word format. Text must be single-spaced, in 12-point Times
New Roman font, and contain no unnecessary formatting (such as text in boxes).
▪ Please make your article concise, even if it is below the word limit.
▪ Qualifications, full affiliation (department, school/faculty, institution, city, country) and contact
details of ALL authors must be provided in the manuscript and in the online submission process.
▪ Abbreviations should be spelt out when first used and thereafter used consistently, e.g.
'intravenous (IV)' or 'Department of Health (DoH)'.
▪ Include sections on Acknowledgements, Conflict of Interest, Author Contributions and Funding
sources. If none is applicable, please state ‘none’.
▪ Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and
haemoglobin (g/dL).
▪ Litres is denoted with an uppercase L e.g. 'mL' for millilitres).
▪ Units should be preceded by a space (except for % and ºC), e.g. '40 kg' and '20 cm' but '50%' and
'19ºC'.
▪ Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b not B for beta,
etc.
▪ Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160.
▪ Quotes should be placed in single quotation marks: i.e. The respondent stated: '...'
▪ Round brackets (parentheses) should be used, as opposed to square brackets, which are reserved
for denoting concentrations or insertions in direct quotes.
▪ If you wish material to be in a box, simply indicate this in the text. You may use the table format
–this is the only exception. Please DO NOT use fill, format lines and so on.
Research 
Guideline word limit: 4 000 words 
Research articles describe the background, methods, results and conclusions of an original research study. 
The article should contain the following sections: introduction, methods, results, discussion and 
conclusion, and should include a structured abstract (see below).  
The introduction should be concise – no more than three paragraphs – on the background to the research 
question and must include references to other relevant published studies that clearly lay out the rationale 
for conducting the study. Some common reasons for conducting a study are: to fill a gap in the literature, 
a logical extension of previous work, or to answer an important clinical question. If other papers related 
to the same study have been published previously, please make sure to refer to them specifically. 
Describe the study methods in as much detail as possible so that others would be able to replicate the 
study should they need to. Results should describe the study sample as well as the findings from the study 
itself, but all interpretation of findings must be kept in the discussion section, which should consider 
primary outcomes first before any secondary or tertiary findings or post-hoc analyses. The conclusion 
should briefly summarise the main message of the paper and provide recommendations for further study. 
Select figures and tables for your paper carefully and sparingly. Use only those figures that provided 
added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text. 
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Structured abstract 
This should be 250-400 words, with the following recommended headings: 
Background: why the study is being done and how it relates to other published work. 
Objectives: what the study intends to find out 
Methods: must include study design, number of participants, description of the intervention, primary and 
secondary outcomes, any specific analyses that were done on the data. 
Results: first sentence must be brief population and sample description; outline the results according to 
the methods described. Primary outcomes must be described first, even if they are not the most 
significant findings of the study. 
Conclusion: must be supported by the data, include recommendations for further study/actions. 
Please ensure that the structured abstract is complete, accurate and clear and has been approved by all 
authors. 
Do not include any references in the abstracts. 
Main article 
All articles are to include the following main sections: Introduction/Background, Methods, Results, 
Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
Objectives (within Introduction/Background): a clear statement of the main aim of the study and the 
major hypothesis tested or research question posed 
Design (within Methods): including factors such as prospective, randomisation, blinding, placebo control, 
case control, crossover, criterion standards for diagnostic tests, etc. 
Setting (within Methods): level of care, e.g. primary, secondary, number of participating centres. 
Participants (instead of patients or subjects; within Methods): numbers entering and completing the 
study, sex, age and any other biological, behavioural, social or cultural factors (e.g. smoking status, 
socioeconomic group, educational attainment, co-existing disease indicators, etc)that may have an impact 
on the study results. Clearly define how participants were enrolled, and describe selection and exclusion 
criteria. 
Interventions (within Methods): what, how, when and for how long. Typically for randomised controlled 
trials, crossover trials, and before and after studies. 
Main outcome measures (within Methods): those as planned in the protocol, and those ultimately 
measured. Explain differences, if any. 
Results 
Start with description of the population and sample. Include key characteristics of comparison groups. 
Main results with (for quantitative studies) 95% confidence intervals and, where appropriate, the exact 
level of statistical significance and the number need to treat/harm. Whenever possible, state absolute 
rather than relative risks. 
Do not replicate data in tables and in text. 
If presenting mean and standard deviations, specify this clearly. Our house style is to present this as 
follows: 
E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean (SD).
Leave interpretation to the Discussion section. The Results section should just report the findings as per
the Methods section.
Discussion 
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Please ensure that the discussion is concise and follows this overall structure – sub-headings are not 
needed: 
Statement of principal findings 
Strengths and weaknesses of the study 
Contribution to the body of knowledge 
Strengths and weaknesses in relation to other studies 
The meaning of the study – e.g. what this study means to clinicians and policymakers 
Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary conclusions and 
their implications, suggesting areas for further research if appropriate. Do not go beyond the data in the 
article. 
 
Illustrations/photos/scans 
▪ If illustrations submitted have been published elsewhere, the author(s) should provide consent to 
republication obtained from the copyright holder. 
▪ Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
▪ Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full). 
▪ All images must be of high enough resolution/quality for print. 
▪ All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form. 
▪ Ensure all graph axes are labelled appropriately, with a heading/description and units (as 
necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 2.0; 3.0; 4.0 etc. 
▪ Scans/photos showing a specific feature e.g. Intermediate magnification micrograph of a low 
malignant potential (LMP) mucinous ovarian tumour. (H&E stain). –include an arrow to show the 
tumour. 
▪ Each image must be attached individually as a 'supplementary file' upon submission (not solely 
embedded in the accompanying manuscript) and named Fig. 1, Fig. 2, etc. 
 
Tables 
▪ Tables should be constructed carefully and simply for intelligible data representation. 
Unnecessarily complicated tables are strongly discouraged. 
▪ Large tables will generally not be accepted for publication in their entirety. Please consider 
shortening and using the text to highlight specific important sections, or offer a large table as an 
addendum to the publication, but available in full on request from the author 
▪ Embed/include each table in the manuscript Word file - do not provide separately as 
supplementary files. 
▪ Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to consecutively in the 
text. 
▪ Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable. 
▪ Ensure each table has a concise title and column headings, and include units where necessary. 
▪ Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ || then ** †† 
‡‡ etc. 
Do not: Use [Enter] within a row to make ‘new rows’: 
Rather: Each row of data must have its own proper row: 
Do not: use separate columns for n and %: 
Rather: Combine into one column, n (%): 
Do not: have overlapping categories, e.g.: 
Rather: Use <> symbols or numbers that don’t overlap: 
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References 
NB: Only complete, correctly formatted reference lists in Vancouver style will be accepted. Reference 
lists must be generated manually and not with the use of reference manager software. Endnotes must not 
be used. 
▪ Authors must verify references from original sources. 
▪ Citations should be inserted in the text as superscript numbers between square brackets, e.g. These 
regulations are endorsed by the World Health Organization, [2] and others.[3,4-6] 
▪ All references should be listed at the end of the article in numerical order of appearance in the 
Vancouver style (not alphabetical order). 
▪ Approved abbreviations of journal titles must be used; see the List of Journals in Index Medicus. 
▪ Names and initials of all authors should be given; if there are more than six authors, the first three 
names should be given followed by et al. 
▪ Volume and issue numbers should be given. 
▪ First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
▪ Wherever possible, references must be accompanied by a digital object identifier (DOI) link). 
Authors are encouraged to use the DOI lookup service offered by CrossRef: 
▪ On the Crossref homepage, paste the article title into the ‘Metadata search’ box. 
▪ Look for the correct, matching article in the list of results. 
▪ Click Actions > Cite 
▪ Alongside 'url =' copy the URL between { }. 
▪ Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x 
 
  
 
